#  @TimCarmichael3 Tim Carmichael Tim Carmichael posts on X about $azn, $vktx, $cytk, $lly the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours. ### Engagements: [---] [#](/creator/twitter::863315184/interactions)  - [--] Week [-----] -59% - [--] Month [------] +68% - [--] Months [-------] +187% - [--] Year [-------] +32% ### Mentions: [--] [#](/creator/twitter::863315184/posts_active)  - [--] Week [--] -41% - [--] Month [---] +36% - [--] Months [---] +172% - [--] Year [---] +33% ### Followers: [-----] [#](/creator/twitter::863315184/followers)  - [--] Week [-----] +0.59% - [--] Month [-----] +1.50% - [--] Months [-----] +9.70% - [--] Year [-----] +27% ### CreatorRank: [---------] [#](/creator/twitter::863315184/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) 64.29% [finance](/list/finance) 23.57% [currencies](/list/currencies) 17.14% [technology brands](/list/technology-brands) 2.86% [exchanges](/list/exchanges) 2.14% [cryptocurrencies](/list/cryptocurrencies) 2.14% [countries](/list/countries) 1.43% [travel destinations](/list/travel-destinations) 0.71% [celebrities](/list/celebrities) 0.71% [gaming](/list/gaming) 0.71% **Social topic influence** [$azn](/topic/$azn) #135, [$vktx](/topic/$vktx) #43, [$cytk](/topic/$cytk) 8.57%, [$lly](/topic/$lly) #57, [$abvx](/topic/$abvx) 7.86%, [$tgtx](/topic/$tgtx) 5.71%, [$srpt](/topic/$srpt) 5%, [strong](/topic/strong) 5%, [flow](/topic/flow) 5%, [ceo](/topic/ceo) 5% **Top accounts mentioned or mentioned by** [@biopharmadive](/creator/undefined) [@troutandchar](/creator/undefined) [@apexonco](/creator/undefined) [@cordenpharma](/creator/undefined) [@wustlbear](/creator/undefined) [@albertbourla](/creator/undefined) [@pharmdca](/creator/undefined) [@stocktilludrop](/creator/undefined) [@mikegoodma](/creator/undefined) [@sellsidesource](/creator/undefined) [@biopharmiq](/creator/undefined) [@lng_investor_](/creator/undefined) [@justin_mcd01](/creator/undefined) [@prosperousguy](/creator/undefined) **Top assets mentioned** [AstraZeneca PLC (AZN)](/topic/$azn) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Cytokinetics Inc. (CYTK)](/topic/$cytk) [Eli Lilly and Company (LLY)](/topic/$lly) [Abivax SA (ABVX)](/topic/$abvx) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Bristol-Myers Squibb Co (BMY)](/topic/$bmy) [Rubrik, Inc. (RBRK)](/topic/$rbrk) [Novo-Nordisk (NVO)](/topic/$nvo) [Pfizer, Inc. (PFE)](/topic/$pfe) [Disc Medicine, Inc. Common Stock (IRON)](/topic/$iron) [Astronics Corp (ATRO)](/topic/$atro) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Merck & Co., Inc. (MRK)](/topic/$mrk) [3M Co (MMM)](/topic/$mmm) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [CoreWeave, Inc (CRWV)](/topic/$crwv) [Coupang, Inc. (CPNG)](/topic/$cpng) [Janux Therapeutics, Inc. (JANX)](/topic/$janx) [Novartis AG (NVS)](/topic/$nvs) [Oracle Corporation (ORCL)](/topic/$orcl) [AbbVie Inc (ABBV)](/topic/$abbv) [Viking Holdings Ltd (VIK)](/topic/$vik) [Structure Therapeutics Inc. (GPCR)](/topic/$gpcr) [Morgan Stanley (MS)](/topic/morgan-stanley) [Sanofi (SNY)](/topic/sanofi) [Synthetify (SNY)](/topic/$sny) [Applied Digital Corp. (APLD)](/topic/$apld) [Goldman Sachs (GS)](/topic/goldman-sachs) [Edgewise Therapeutics, Inc. (EWTX)](/topic/$ewtx) [Moderna Inc (MRNA)](/topic/$mrna) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [Eaton Corporation PLC (ETN)](/topic/eaton-corp) [Electroneum (ETN)](/topic/$etn) [Insmed, Inc. (INSM)](/topic/$insm) [Acadia Pharmaceuticals Inc. (ACAD)](/topic/$acad) [Jazz Pharmaceuticals, Inc. (JAZZ)](/topic/$jazz) [Joby Aviation, Inc. (JOBY)](/topic/$joby) [Seagen Inc (SGEN)](/topic/$sgen) [Bitcoin (BTC)](/topic/bitcoin) [Strategy (MSTR)](/topic/$mstr) [BioMarin Pharmaceutical, Inc. (BMRN)](/topic/$bmrn) ### Top Social Posts Top posts by engagements in the last [--] hours "$VKTX++ getting FDA approval to skip a trial phase & move directly into Phase [--] significantly accelerates their development time in the GLP1 market. Lots to like here in this small cap obesity play. Accelerating timelines should increase the pressure on the HUGE short position betting against VK2735. This has the makings of a potential powder keg 🚀🚀🚀 https://twitter.com/i/web/status/2021941537899151517 https://twitter.com/i/web/status/2021941537899151517" [X Link](https://x.com/TimCarmichael3/status/2021941537899151517) 2026-02-12T13:36Z [----] followers, [----] engagements "$IRON two months ago it was an overreaction . Today it was a heart piercing CRL Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://t.co/WzW3kfHAgk Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://t.co/WzW3kfHAgk" [X Link](https://x.com/TimCarmichael3/status/2022422869784039835) 2026-02-13T21:29Z [----] followers, [---] engagements "Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Sarepta Therapeutics Inc. $SRPT https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study" [X Link](https://x.com/TimCarmichael3/status/2014829997555360079) 2026-01-23T22:37Z [----] followers, [---] engagements "VKTX Stock Rallies After Hours On Optimism Around Companys Obesity Pipeline. $VKTX https://stocktwits.com/news-articles/markets/equity/vktx-stock-rallies-after-hours-on-optimism-around-companys-obesity-portfolio/cZb6MYxR4Ak https://stocktwits.com/news-articles/markets/equity/vktx-stock-rallies-after-hours-on-optimism-around-companys-obesity-portfolio/cZb6MYxR4Ak" [X Link](https://x.com/TimCarmichael3/status/2021732671303692324) 2026-02-11T23:46Z [----] followers, [---] engagements "BridgeBio scores with dwarfism drug setting up showdown with BioMarin Ascendis via @BioPharmaDive. $BBIO https://www.biopharmadive.com/news/bridgebio-dwarfism-drug-data-infigratinib-achondroplasia-biomarin-ascendis/812034/ https://www.biopharmadive.com/news/bridgebio-dwarfism-drug-data-infigratinib-achondroplasia-biomarin-ascendis/812034/" [X Link](https://x.com/TimCarmichael3/status/2021938013815656931) 2026-02-12T13:22Z [----] followers, [---] engagements "Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd" [X Link](https://x.com/TimCarmichael3/status/2002936354741920016) 2025-12-22T02:56Z [----] followers, [---] engagements "Astronics Corporation Announces Preliminary Unaudited Revenue for Fourth Quarter [----] and Initiates Revenue Guidance for [----] - Business Wire $ATRO https://stocks.apple.com/ArSUKm62KQTOAjE1ybLXOlA https://stocks.apple.com/ArSUKm62KQTOAjE1ybLXOlA" [X Link](https://x.com/TimCarmichael3/status/2009278506136388007) 2026-01-08T14:58Z [----] followers, [---] engagements "$ETN US Senator on Energy Committee buying stock think he knows anything PENDING BREAKING: Senator John Hickenlooper filed a purchase of up to $100000 of stock in Eaton Corporation. Eaton is a power management company. Hickenlooper sits on the Senate Committee on Energy. We'll be keeping an eye on $ETN. https://t.co/S1l1yDnQCF BREAKING: Senator John Hickenlooper filed a purchase of up to $100000 of stock in Eaton Corporation. Eaton is a power management company. Hickenlooper sits on the Senate Committee on Energy. We'll be keeping an eye on $ETN. https://t.co/S1l1yDnQCF" [X Link](https://x.com/TimCarmichael3/status/2021056963065544922) 2026-02-10T03:01Z [----] followers, [---] engagements "$IRON good thing they did a $250 million stock offering at $84 share [--] months ago $IRON two months ago it was an overreaction . Today it was a heart piercing CRL $IRON two months ago it was an overreaction . Today it was a heart piercing CRL" [X Link](https://x.com/TimCarmichael3/status/2022425531405521224) 2026-02-13T21:39Z [----] followers, [---] engagements "Wall Street eyes upside for Insmed after Brinsupri sales beat $INSM https://www.fiercepharma.com/pharma/insmed-blowout-brinsupri-sales-beat-fuels-multi-blockbuster-outlook https://www.fiercepharma.com/pharma/insmed-blowout-brinsupri-sales-beat-fuels-multi-blockbuster-outlook" [X Link](https://x.com/TimCarmichael3/status/2009726146318086391) 2026-01-09T20:37Z [----] followers, [---] engagements "$AXSM a wonderful mid cap story with a dynamic product portfolio. This one is certainly on the M&A screens at BigBioPharma 💥💥💥 Piper Sandler $AXSM's PT to $223 from $148 reiterated at an Overweight and said 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Piper Sandler Additionally said: We met with Axsome senior management recently and gained more insights into commercial dynamics Piper Sandler $AXSM's PT to $223 from $148 reiterated at an Overweight and said 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Piper Sandler Additionally said: We met with Axsome senior" [X Link](https://x.com/TimCarmichael3/status/2012185851590291947) 2026-01-16T15:31Z [----] followers, [---] engagements "$JANX thank goodness they were able to raise $350 million at $63 sh [--] weeks ago only to turn back into a pre-teenager almost overnight. Lots of bag holders still in this name (luckily not me)" [X Link](https://x.com/TimCarmichael3/status/2014391899608539628) 2026-01-22T17:37Z [----] followers, [---] engagements "Bristol Myers buys into Januxs masked T cell engagers BioPharma Dive $JANX $BMY https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/ https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/" [X Link](https://x.com/TimCarmichael3/status/2014404706227904831) 2026-01-22T18:28Z [----] followers, [---] engagements "$TGTX strong retention rates for BRIUMVI lock for a strong [----] $TGTX important observation occurring-Retention &Duration - recent social media checks showing large numbers of #Bruimvi patients on therapy now [--] years [--] yrs even [--] years - with no new lesions or relapses - many quoting best they ever felt - patients switching to BRIUMVI are $TGTX important observation occurring-Retention &Duration - recent social media checks showing large numbers of #Bruimvi patients on therapy now [--] years [--] yrs even [--] years - with no new lesions or relapses - many quoting best they ever felt - patients" [X Link](https://x.com/TimCarmichael3/status/2015546618519408897) 2026-01-25T22:05Z [----] followers, [---] engagements "Joby Aviation Stock Plunges. This Is Why. $JOBY https://www.barrons.com/articles/joby-aviation-stock-electric-taxi-3ee74440st=6yoxad https://www.barrons.com/articles/joby-aviation-stock-electric-taxi-3ee74440st=6yoxad" [X Link](https://x.com/TimCarmichael3/status/2016889930882904525) 2026-01-29T15:03Z [----] followers, [---] engagements "$TGTX dont overlook this solid growth story💥💥💥 B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note: https://t.co/pf2vEhV78g B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note: https://t.co/pf2vEhV78g" [X Link](https://x.com/TimCarmichael3/status/2019036231456457176) 2026-02-04T13:12Z [----] followers, [---] engagements "$PFE any meaningful update on the $43 billion $SGEN acquisition I see impairment charges but no cartwheels on how great things are going there. $PFE management continues to be a disaster. $PFE MGT yesterday excited about GLP1+ amylin combo ( still on phase 1) potential BIC . look at early phase [--] with small doses how nausea / vomit are synergistic. Tiny doses of Met097 ( [---] ) and [---] ( o.3) in combo result in nausea and vomit while higher doses of each alone ( https://t.co/dh4Q9tbCbR $PFE MGT yesterday excited about GLP1+ amylin combo ( still on phase 1) potential BIC . look at early phase 1" [X Link](https://x.com/TimCarmichael3/status/2019040429484933559) 2026-02-04T13:28Z [----] followers, [---] engagements "$VKTX lets see if management can give shareholders a little love. Theres a lot of value in this small cap gem will it ever be unlockedit sure looks like its undervalued 💥💥💥 Viking Therapeutics to Report Financial Results for Second Quarter [----] on July [--] [----] https://t.co/GhRAixNfhJ Viking Therapeutics to Report Financial Results for Second Quarter [----] on July [--] [----] https://t.co/GhRAixNfhJ" [X Link](https://x.com/TimCarmichael3/status/2019278874295906653) 2026-02-05T05:16Z [----] followers, [----] engagements "Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. https://www.barrons.com/articles/bristol-myers-earnings-stock-price-8a5e147cst=oyMCqr https://www.barrons.com/articles/bristol-myers-earnings-stock-price-8a5e147cst=oyMCqr" [X Link](https://x.com/TimCarmichael3/status/2019388222497829165) 2026-02-05T12:30Z [----] followers, [---] engagements "$AZN do you do any fact checking before you comment AZN just changed the listing to the NYSE from OTC ADS. Do you use a computer It's amazing how much AZN stock popped Monday and equally amazing that it held most of the 100%-plus gain Tuesday. https://t.co/lWXtYyCQ72 It's amazing how much AZN stock popped Monday and equally amazing that it held most of the 100%-plus gain Tuesday. https://t.co/lWXtYyCQ72" [X Link](https://x.com/TimCarmichael3/status/2019803779923890346) 2026-02-06T16:02Z [----] followers, [----] engagements "$EIKN what a joke Who ran the books on this POS How embarrassing. $EIKN prices at $18/share to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI $EIKN prices at $18/share to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI" [X Link](https://x.com/TimCarmichael3/status/2019805368600379851) 2026-02-06T16:08Z [----] followers, [---] engagements "$ORCL downgrade $ORCL : Melius downgrades to sets $ Analyst flags weak cash generation AI monetization uncertainty and sees limited upside as value may be absorbed by debt and dilution https://t.co/vaCwWmW2tW $ORCL : Melius downgrades to sets $ Analyst flags weak cash generation AI monetization uncertainty and sees limited upside as value may be absorbed by debt and dilution https://t.co/vaCwWmW2tW" [X Link](https://x.com/TimCarmichael3/status/2020897343868952718) 2026-02-09T16:27Z [----] followers, [---] engagements "$RBRK after last Q results company raised guidance significantlypushing stock back into $90s. Upcoming results could force a MAJOR short covering rally as the fundamentals remain very compelling in the cybersecurity space. Risk/reward for both traders and investors looks VERY ATTRACTIVE at current levels on this small cap beauty💥💥💥💥 $RBRK had its best checks in +5 years with a competitor's issues mainly idiosyncratic. Expecting +10% sales / 2% ARR upside though stock will likely trade on FY27 initial guide primarily where our math implies $1.8B ARR and low-20s sales growth - Piper $RBRK" [X Link](https://x.com/TimCarmichael3/status/2021090432541692216) 2026-02-10T05:14Z [----] followers, [---] engagements "$AZN ++ what a powerhouse $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative" [X Link](https://x.com/TimCarmichael3/status/2021197563123335183) 2026-02-10T12:20Z [----] followers, [---] engagements "AstraZeneca's oral GLP-1 scored phase [--] wins but no data yet $AZN https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data" [X Link](https://x.com/TimCarmichael3/status/2021275932602888460) 2026-02-10T17:31Z [----] followers, [----] engagements "AZ sets sights on 25+ blockbusters by [----] $AZN https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition" [X Link](https://x.com/TimCarmichael3/status/2021282264470991101) 2026-02-10T17:57Z [----] followers, [---] engagements "AZ sets sights on 25+ blockbusters by [----]. $AZN https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition" [X Link](https://x.com/TimCarmichael3/status/2021341877233225894) 2026-02-10T21:53Z [----] followers, [---] engagements "Strategys Michael Saylor Doubles Down on Bitcoin. Wall Street Is Shorting the Stock. $MSTR https://www.barrons.com/articles/strategy-stock-price-bitcoin-short-interest-michael-saylor-mstr-9e6f5c83st=8hnzCE https://www.barrons.com/articles/strategy-stock-price-bitcoin-short-interest-michael-saylor-mstr-9e6f5c83st=8hnzCE" [X Link](https://x.com/TimCarmichael3/status/2021362989207552488) 2026-02-10T23:17Z [----] followers, [---] engagements "AstraZeneca Teases Very Competitive Weight-Loss PillBut Stays Mum on Details - BioSpace. $AZN https://www.biospace.com/business/astrazeneca-teases-very-competitive-weight-loss-pill-but-stays-mum-on-details https://www.biospace.com/business/astrazeneca-teases-very-competitive-weight-loss-pill-but-stays-mum-on-details" [X Link](https://x.com/TimCarmichael3/status/2021625241475178916) 2026-02-11T16:39Z [----] followers, [---] engagements "$AZN ++ new [--] week & all-time high 💥💥💥 $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative" [X Link](https://x.com/anyuser/status/2021675930255831497) 2026-02-11T20:01Z [----] followers, [---] engagements "$VKTX ++ this story is starting to ramp nicely [----] looks to be a nice year for investor returns.💥💥 $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY" [X Link](https://x.com/anyuser/status/2021723110727180549) 2026-02-11T23:08Z [----] followers, [---] engagements "$BMRN one of the top boring biotech of all-time. Nobody would ever step up and buy this company & put it out of investors memory. I held $BMRN for over [--] years thinking it was a no brainer takeover at some point (sold it last year) Funny that they now are a buyer deal actually make lots of sense and the stock should be up today I held $BMRN for over [--] years thinking it was a no brainer takeover at some point (sold it last year) Funny that they now are a buyer deal actually make lots of sense and the stock should be up today" [X Link](https://x.com/TimCarmichael3/status/2002008846546432129) 2025-12-19T13:31Z [----] followers, [---] engagements "$VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in [----]. Remember that many large BioPharmas dont have representation in the $150+ billion Diabesity market - the largest market out there. $ABBV $MRK $BMY and others could EASILY write a $10 billion check to get the best science on the cusp of PRIMETIME. They already have infrastructure-R&D manufacturing marketing and could drop VK2735 right into their product portfolio. This" [X Link](https://x.com/TimCarmichael3/status/2019517359644450842) 2026-02-05T21:03Z [----] followers, 11.4K engagements "$VKTX++ this one is starting to ramp up - look for [----] to be a fruitful year for shareholders 💥💥 $VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in [----]. Remember that many large BioPharmas dont have $VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in 2026." [X Link](https://x.com/TimCarmichael3/status/2021725028107079725) 2026-02-11T23:16Z [----] followers, [----] engagements "$VKTX $VKTX $LLY $NVO 🚨 EARNINGS CALL SIGNAL VIKING THERAPEUTICS LEADERSHIP SPECIFIES THAT THEIR AGREEMENT WITH API/FINISH/FILL PARTNER @cordenpharma IS FULLY TRANSFERABLE $VKTX $LLY $NVO 🚨 EARNINGS CALL SIGNAL VIKING THERAPEUTICS LEADERSHIP SPECIFIES THAT THEIR AGREEMENT WITH API/FINISH/FILL PARTNER @cordenpharma IS FULLY TRANSFERABLE" [X Link](https://x.com/TimCarmichael3/status/2021796127826186643) 2026-02-12T03:58Z [----] followers, [---] engagements "$VKTX ++ What the analysts not highlighting from $LLY Attain -maintain statement that Gi AEs were C/W with other incretins. Unless lilly employs very sloppy top line writer it suggests 15-30 % vomit rate when switching from tirzepatide to orforglipron despite likely slow What the analysts not highlighting from $LLY Attain -maintain statement that Gi AEs were C/W with other incretins. Unless lilly employs very sloppy top line writer it suggests 15-30 % vomit rate when switching from tirzepatide to orforglipron despite likely slow" [X Link](https://x.com/TimCarmichael3/status/2021937662740054478) 2026-02-12T13:21Z [----] followers, [---] engagements "Anthropic closes $30 billion funding round as cash keeps flowing into top AI startups https://cnb.cx/46NqyN3 https://cnb.cx/46NqyN3" [X Link](https://x.com/TimCarmichael3/status/2022041703457399110) 2026-02-12T20:14Z [----] followers, [--] engagements "Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://stocks.apple.com/AiQlbBBKpQTawPwfuoDGNXA https://stocks.apple.com/AiQlbBBKpQTawPwfuoDGNXA" [X Link](https://x.com/TimCarmichael3/status/2022044185109704971) 2026-02-12T20:24Z [----] followers, [---] engagements "$MMM++ new [--] week high & highest value over last [--] years. Beware the talking head💥💥💥 Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://t.co/GlEkksBC3P Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://t.co/GlEkksBC3P" [X Link](https://x.com/TimCarmichael3/status/2022045336613925266) 2026-02-12T20:29Z [----] followers, [---] engagements "Coatue founder Philippe Laffont: The world is moving to the token economy https://cnb.cx/4rSPkDS https://cnb.cx/4rSPkDS" [X Link](https://x.com/TimCarmichael3/status/2022447935322050626) 2026-02-13T23:08Z [----] followers, [--] engagements "$VKTX $CYTK $TGTX #JPM2026 The JPMorgan Healthcare Conference is just around the corner and takes place in SF from January 12-15 [----] and is the largest gathering of healthcare companies executives and investors in the world. The conference has annually served as an event where M&A fireworks take place with many deals both big and small taking place. Stay tuned it promises to an exciting conference for investors.💥💥💥💥" [X Link](https://x.com/TimCarmichael3/status/1996680467308073118) 2025-12-04T20:38Z [----] followers, [----] engagements "$RBRK over [----] million shares sold short🚀🚀 $RBRK++ solid Q great earning& revenues raising forward guidancemiss to investors ears $RBRK++ solid Q great earning& revenues raising forward guidancemiss to investors ears" [X Link](https://x.com/TimCarmichael3/status/1996692095160275340) 2025-12-04T21:24Z [----] followers, [---] engagements "$VKTX++ hope springs eternal Still [--] million shares sold short & betting against VK2735💥💥💥 $VKTX FDA Pathway Catalyst Incoming The Real Catalyst Nobodys Talking About Everyones staring at charts while the actual event that could reprice Viking overnight is happening right under the radar: The FDA meeting on the ORAL VK2735 pathway. Heres the deal: $VKTX FDA Pathway Catalyst Incoming The Real Catalyst Nobodys Talking About Everyones staring at charts while the actual event that could reprice Viking overnight is happening right under the radar: The FDA meeting on the ORAL VK2735 pathway." [X Link](https://x.com/TimCarmichael3/status/1996711838139273258) 2025-12-04T22:42Z [----] followers, [----] engagements "$RBRK++ visibility has increased company guidance bullish $RBRK Rubrik Inc. (RBRK) Analyst Price Targets https://t.co/kM0NsjPta7 $RBRK Rubrik Inc. (RBRK) Analyst Price Targets https://t.co/kM0NsjPta7" [X Link](https://x.com/TimCarmichael3/status/1996946835450032178) 2025-12-05T14:16Z [----] followers, [---] engagements "Praxis soars higher; Bristol Myers CAR-T therapy wins broader use via @BioPharmaDive https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-12-05%20BioPharma%20Dive%20%5Bissue:79517%5D&utm_term=BioPharma%20Dive https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-12-05%20BioPharma%20Dive%20%5Bissue:79517%5D&utm_term=BioPharma%20Dive" [X Link](https://x.com/TimCarmichael3/status/1996985772193276245) 2025-12-05T16:51Z [----] followers, [---] engagements "$TER story remains on solid footing & new players like Stifel continue to gravitate to the company. New [--] week high💥💥 $TER Upgrading Teradyne to Buy: Narrative shift revenue shift and +optionality in AI compute too important to ignore https://t.co/BTAsOlbf0k $TER Upgrading Teradyne to Buy: Narrative shift revenue shift and +optionality in AI compute too important to ignore https://t.co/BTAsOlbf0k" [X Link](https://x.com/TimCarmichael3/status/1997004451136077901) 2025-12-05T18:05Z [----] followers, [---] engagements "$OCUL $OCUL JMP BUY PT $29 new regulatory strategy could get Axpaxli approved at least a year earlier than previously anticipated&make it first long- acting TKI available to wet AMD patients.This is a bold move with limited downside in our view as $OCUL could simply resubmit a more $OCUL JMP BUY PT $29 new regulatory strategy could get Axpaxli approved at least a year earlier than previously anticipated&make it first long- acting TKI available to wet AMD patients.This is a bold move with limited downside in our view as $OCUL could simply resubmit a more" [X Link](https://x.com/TimCarmichael3/status/1997847104136651055) 2025-12-08T01:54Z [----] followers, [---] engagements "$SRPT ++ hair on this dog but an outstanding speculation on a risk/reward play💥💥💥 Agree - $SRPT is my second largest long. It will rip back to $50. One of the Most Misunderstood Biotechs on the Market in my opinion. Some people see Sarepta as a company in trouble. I see it as a multi-bagger After going through the latest numbers regulatory updates and Agree - $SRPT is my second largest long. It will rip back to $50. One of the Most Misunderstood Biotechs on the Market in my opinion. Some people see Sarepta as a company in trouble. I see it as a multi-bagger After going through the latest" [X Link](https://x.com/TimCarmichael3/status/1997865968727724068) 2025-12-08T03:09Z [----] followers, [---] engagements "$RARE ascending triple top breakout today💥💥💥 $XBI long $ASND $RARE $XENE $ROIV https://t.co/dkbDCQhuu9 $XBI long $ASND $RARE $XENE $ROIV https://t.co/dkbDCQhuu9" [X Link](https://x.com/TimCarmichael3/status/1998045855065264590) 2025-12-08T15:03Z [----] followers, [---] engagements "$AZN++ lots to like in this story. Look for a big year in 2026💥💥 Early findings for AstraZeneca's dual-targeted CAR-T show 100% ORR in MM #ASH25 $AZN https://t.co/ey6m2YcbyK Early findings for AstraZeneca's dual-targeted CAR-T show 100% ORR in MM #ASH25 $AZN https://t.co/ey6m2YcbyK" [X Link](https://x.com/TimCarmichael3/status/1998099021534212452) 2025-12-08T18:35Z [----] followers, [---] engagements "$VKTK $NVO $LLY $GPCR $NVO with failed acquisition of MTSR I believe they will make another bold move to hunt for Obesity acquisition $VKTX or $GPCR Surprise good data from $GPCR this morning and market cap not much expensive considering MTSR recent acquisition $VKTX my bold prediction- It will $NVO with failed acquisition of MTSR I believe they will make another bold move to hunt for Obesity acquisition $VKTX or $GPCR Surprise good data from $GPCR this morning and market cap not much expensive considering MTSR recent acquisition $VKTX my bold prediction- It will" [X Link](https://x.com/TimCarmichael3/status/1998125714936299822) 2025-12-08T20:21Z [----] followers, [---] engagements "$ABVX option buyers paying over $5/contract for Dec180 calls need a [--] point move in $ABVX to BREAK EVEN Crazy world $ABVX [---] C 12/19/2025 Vol: [---] OI: [---] Avg: $3.89 Prem: $310640 https://t.co/gSVzLf44Kg $ABVX [---] C 12/19/2025 Vol: [---] OI: [---] Avg: $3.89 Prem: $310640 https://t.co/gSVzLf44Kg" [X Link](https://x.com/TimCarmichael3/status/1998420341975384221) 2025-12-09T15:51Z [----] followers, [----] engagements "French biotech Abivax's shares climb on Eli Lilly bid rumors Reuters. $LLY. $ABVX https://www.reuters.com/business/healthcare-pharmaceuticals/french-biotech-abivaxs-shares-climb-eli-lilly-bid-rumors-2025-12-10/ https://www.reuters.com/business/healthcare-pharmaceuticals/french-biotech-abivaxs-shares-climb-eli-lilly-bid-rumors-2025-12-10/" [X Link](https://x.com/TimCarmichael3/status/1998749488622502232) 2025-12-10T13:39Z [----] followers, [----] engagements "$RBRK momentum continues to build💥💥💥 $RBRK just delivered a Top-1% AI earnings print AND triggered a Quad-MA Ignition Candle this combo is EXTREMELY rare. Most people still dont understand how insane this setup is. This wasnt a beat. This was a system-level upgrade for the entire RBRK story. Highlights that https://t.co/LSrGO6cPpH $RBRK just delivered a Top-1% AI earnings print AND triggered a Quad-MA Ignition Candle this combo is EXTREMELY rare. Most people still dont understand how insane this setup is. This wasnt a beat. This was a system-level upgrade for the entire RBRK story." [X Link](https://x.com/TimCarmichael3/status/1998769033857085487) 2025-12-10T14:57Z [----] followers, [---] engagements "$LLY $ABVX the Obesity Gravy Train continues roll on for $LLY - market continues to grow & company market share continues to expand over $NVO. This gives CEO Dave Ricks the perfect opportunity to expand his product portfolio & he has the cash flow to do it. Whether hes in Paris currently dining on fine French cuisine & a hearty Bordeaux or negotiating terms with $ABVX is anybodys guess. But the key is hes in the driver seat as far as M&A and the market is likely to reward $LLY if he pulls the trigger.💥💥💥" [X Link](https://x.com/TimCarmichael3/status/1998859314853761433) 2025-12-10T20:56Z [----] followers, [----] engagements "$PFE Morgan Stanley lowered their PT from $32 to $28 and lowered earnings estimates for 25/26 in front of December [--] company guidance call. The Bourla Dumpster Fire continues" [X Link](https://x.com/TimCarmichael3/status/1999484163066663006) 2025-12-12T14:19Z [----] followers, [---] engagements "Democrats released a selection of photos obtained from Jeffrey Epsteins estate that include pictures of President Trump and former President Bill Clinton https://www.wsj.com/politics/democrats-release-epstein-estate-photos-showing-donald-trump-bill-clinton-7fe21bd2st=TZpYJ2 https://www.wsj.com/politics/democrats-release-epstein-estate-photos-showing-donald-trump-bill-clinton-7fe21bd2st=TZpYJ2" [X Link](https://x.com/TimCarmichael3/status/1999502720290451560) 2025-12-12T15:32Z [----] followers, [---] engagements "$ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥" [X Link](https://x.com/TimCarmichael3/status/1999545897504366814) 2025-12-12T18:24Z [----] followers, [---] engagements "$ATRO triple top breakout 💥💥 $ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥 $ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥" [X Link](https://x.com/TimCarmichael3/status/1999569953721090087) 2025-12-12T20:00Z [----] followers, [---] engagements "$KYMR++ Baker Brothers bought [--] million shares @ $86/share. Among the best in biotech investing 💥💥💥 $KYMR Baker bros acquiring $172 million dollars worth of $KYMR at open market $XBI $IBB P2 Atopic dermatitis [----] https://t.co/beo19T6x5K $KYMR Baker bros acquiring $172 million dollars worth of $KYMR at open market $XBI $IBB P2 Atopic dermatitis [----] https://t.co/beo19T6x5K" [X Link](https://x.com/TimCarmichael3/status/2000348757846823165) 2025-12-14T23:34Z [----] followers, [---] engagements "Sanofi's tolebrutinib woes pile up with FDA delay trial miss $SNY https://www.fiercebiotech.com/biotech/sanofis-tolebrutinib-woes-pile-fda-delay-trial-miss https://www.fiercebiotech.com/biotech/sanofis-tolebrutinib-woes-pile-fda-delay-trial-miss" [X Link](https://x.com/TimCarmichael3/status/2000626187127718284) 2025-12-15T17:57Z [----] followers, [---] engagements "CoreWeaves Staggering Fall From Market Grace Highlights AI Bubble Fears - The Wall Street Journal $CRWV https://stocks.apple.com/AQc26cpqKQ9eTv-X--dKCpw https://stocks.apple.com/AQc26cpqKQ9eTv-X--dKCpw" [X Link](https://x.com/TimCarmichael3/status/2000963088707690999) 2025-12-16T16:15Z [----] followers, [---] engagements "Enhertu combo cleared for use in frontline breast cancer BioPharma Dive $AZN https://www.biopharmadive.com/news/enhertu-fda-approval-first-line-her2-breast-cancer/807969/ https://www.biopharmadive.com/news/enhertu-fda-approval-first-line-her2-breast-cancer/807969/" [X Link](https://x.com/TimCarmichael3/status/2000989618481889288) 2025-12-16T18:01Z [----] followers, [---] engagements "Pfizer unveils [----] guidance triggering 5% share price decline $PFE https://www.fiercepharma.com/pharma/pfizer-shares-drop-5-2026-revenue-projection-and-long-range-outlook https://www.fiercepharma.com/pharma/pfizer-shares-drop-5-2026-revenue-projection-and-long-range-outlook" [X Link](https://x.com/TimCarmichael3/status/2001025244660957537) 2025-12-16T20:22Z [----] followers, [--] engagements "Gone are the bear days for biotech William Blair thinks so https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says" [X Link](https://x.com/TimCarmichael3/status/2001320689903554650) 2025-12-17T15:56Z [----] followers, [---] engagements "$APLD looks like the finger in the dike is having trouble holding. It looks like short seller Jim Chanos and his message on names like $CRWV $RGTI $APLD are getting some meaningful traction" [X Link](https://x.com/TimCarmichael3/status/2001322909726572996) 2025-12-17T16:05Z [----] followers, [---] engagements "$APLD cant seem to catch much of a bid continue to fall like a hot knife through butter. Sure trades like those with profits are locking them in & those who dont locking in their losses for the tax man. I guess one can always come back to $APLD if/when it settles down hard to know when $ORCL $CRWV and many others are hemorrhaging. $APLD @WUSTL_Bear are you just going to continue to let the stock fall without giving any assurance to your shareholders Down 50% since earnings and you keep saying these new hyperscaler deals are coming $APLD @WUSTL_Bear are you just going to continue to let the" [X Link](https://x.com/TimCarmichael3/status/2001429261274505236) 2025-12-17T23:08Z [----] followers, [---] engagements "$ABVX Guggenheim raised TP to $175 Top Pick for [----] $ABVX . Abivax (ABVX) said late Thursday it will be added to the Nasdaq Biotechnology Index prior to market open on Dec. [--]. The index is reviewed annually in December and is calculated under a modified capitalization-weighted methodology the clinical-stage biotechnology https://t.co/QL7YLa4fHE $ABVX . Abivax (ABVX) said late Thursday it will be added to the Nasdaq Biotechnology Index prior to market open on Dec. [--]. The index is reviewed annually in December and is calculated under a modified capitalization-weighted methodology the" [X Link](https://x.com/TimCarmichael3/status/2002020730414719152) 2025-12-19T14:18Z [----] followers, [----] engagements "Kennedy Center adds Trumps name to building https://www.washingtonpost.com/entertainment/2025/12/19/trump-kennedy-center-sign/ https://www.washingtonpost.com/entertainment/2025/12/19/trump-kennedy-center-sign/" [X Link](https://x.com/TimCarmichael3/status/2002045853611999482) 2025-12-19T15:58Z [----] followers, [--] engagements "$CYTK Nice seeing $GS getting back into game Upgrade BUY $95 PT For those not awareone of the smartest healthcare teams (TRowePrice) now hold over [--] million shares bought over the last [--] months and have become the #1 institutional holder. If walls could only speak . [----] will be a wonderful year for $CYTK and their shareholders 💥 Goldman Sachs $CYTK to Buy/$95 from Neutral/$55 $BMY $EWTX Goldman Sachs said: Emerging data cuts from ODYSSEY-HCM increasingly support a view BMY' trial missed primarily due to drug exposure and study execution issues rather than mechanistic issues with cardiac" [X Link](https://x.com/TimCarmichael3/status/2002049341414867368) 2025-12-19T16:12Z [----] followers, [----] engagements "$INFY is Santa Claus coming to town What up here Is crazy man Trump doing something with HB1 visas Are his friends getting in front of an announcement Sure wouldnt be the first time what is happening in #INFY #ADR up 40% https://t.co/AnTCLKOz2Q what is happening in #INFY #ADR up 40% https://t.co/AnTCLKOz2Q" [X Link](https://x.com/TimCarmichael3/status/2002051588635111644) 2025-12-19T16:21Z [----] followers, [---] engagements "$ABVX the story continues to unfold💥💥💥 $ABVX Obe acting directly on fibroblasts is totally unexpected. It suggests: A 2-pronged mechanism particularly relevant for CD Cell-based proof for the holy grail in CD - reversal of fibrosis It makes CD prospects much more interesting with Obe as a potential game changer https://t.co/MYAKKmE8wg $ABVX Obe acting directly on fibroblasts is totally unexpected. It suggests: A 2-pronged mechanism particularly relevant for CD Cell-based proof for the holy grail in CD - reversal of fibrosis It makes CD prospects much more interesting with Obe as a" [X Link](https://x.com/TimCarmichael3/status/2002079685858242859) 2025-12-19T18:12Z [----] followers, [----] engagements "Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYTK https://www.biospace.com/drug-development/cytokinetics-moment-of-truth-can-aficamten-take-on-bms-in-hypertrophic-cardiomyopathy https://www.biospace.com/drug-development/cytokinetics-moment-of-truth-can-aficamten-take-on-bms-in-hypertrophic-cardiomyopathy" [X Link](https://x.com/TimCarmichael3/status/2002100472656843100) 2025-12-19T19:35Z [----] followers, [---] engagements "$CYTK Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYKT https://t.co/xMdG0kUtTv Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYKT https://t.co/xMdG0kUtTv" [X Link](https://x.com/TimCarmichael3/status/2002100842531606673) 2025-12-19T19:36Z [----] followers, [----] engagements "$CYTK solid label will favor Aficamten with prescribing physicians. They know the game and the hoops they have to go through with $BMY Camzyous. Now patients have a more efficacious option with better data backing it up. When we get the data from AcaciaHCM if it is positive will give $CYTK the throne in both nHCM and oHCM. This will lead to an awesome [----] and shareholders and HCM patients will amply rewarded💥💥💥 $CYTK compares well to Camzyos Here is Camzios box warning Key differences: Reduce dose of aficamten (CYTK) if LVEF [--] Interrupt [--] Camzios - interrupt [--] Camzios has other" [X Link](https://x.com/TimCarmichael3/status/2002232959428972835) 2025-12-20T04:21Z [----] followers, [----] engagements "$CYTK the outlook continues to be stronger for MyQorzo as the FDA approval is granted. [----] has the potential to be a big year for investors with the ACACIA-HCM results on the horizon. Look for a packed house when they present at JPM Healthcare Conference in mid January. I will bet dollars to donuts that BigBioPharma is doing a deep analysis on this one💥💥💥 $CYTK Cantor Impact valuation.peak overall revenue estimates have increased to $7.2bn (from $6.7bn) with peak WW Myqorzo sales of $6.0bn (from $5.5bn) roughly 70% from oHCM. value $CYTK shares using a sum-of-the-parts NPV analysis (10%" [X Link](https://x.com/TimCarmichael3/status/2002938372499673291) 2025-12-22T03:04Z [----] followers, [----] engagements "$AZN no sleeping on AstraZeneca. They are being aggressive on every front & have demonstrated the muscle to attack on every sector. I like their financial discipline and strategic planning. Momentum looks solid in 2026💥💥💥 $AZN is going after $RVMD with preclinical assets from China 👍 jab-23e73 currently in ph1/2a Expected completion 11-2027 (1a/b) and 02-2028 (2a) [--] cohorts: CRC PRAC Other solids $AZN is going after $RVMD with preclinical assets from China 👍 jab-23e73 currently in ph1/2a Expected completion 11-2027 (1a/b) and 02-2028 (2a) [--] cohorts: CRC PRAC Other solids" [X Link](https://x.com/TimCarmichael3/status/2002957700200837227) 2025-12-22T04:21Z [----] followers, [---] engagements "$ABVX $LLY it sure looks like momentum for an acquisition is continuing 🚀🚀🚀 French newspaper with some breaking news this morning $abvx US Giant Eli Lilly Courts Bercy in Move to Acquire Biotech Firm Abivax A delegation from the pharmaceutical group visited the General Directorate of the Treasury in early December. The meeting was intended to subject a https://t.co/6oCy2kp0Gu French newspaper with some breaking news this morning $abvx US Giant Eli Lilly Courts Bercy in Move to Acquire Biotech Firm Abivax A delegation from the pharmaceutical group visited the General Directorate of the" [X Link](https://x.com/TimCarmichael3/status/2003090988894671033) 2025-12-22T13:11Z [----] followers, [----] engagements "$CYTK if Aficamten can follow up with positive data from ACACIA-HCM as GS sees as likely - it will position the company to be able to address BOTH oHCM and nHCM. This will be greeted as great news by investors and increase the attractiveness to BigBioPharmas for sure. [----] looks to be a potentially great year for $CYTK💥💥💥 $CYTK GS Emerging data cuts from ODYSSEY-HCM increasingly support a view $BMY' trial missed primarily due to drug exposure &study execution issues rather than mechanistic issues with cardiac myosin inhibitionthinks that CYTK has likely addressed these issues with" [X Link](https://x.com/TimCarmichael3/status/2003114762729553964) 2025-12-22T14:45Z [----] followers, [---] engagements "Cytokinetics set to battle Bristol Myers as FDA approves heart drug - BioPharma Dive $CYTK https://stocks.apple.com/ACFrW9kquRG6X67JCXodqlA https://stocks.apple.com/ACFrW9kquRG6X67JCXodqlA" [X Link](https://x.com/TimCarmichael3/status/2003119318893039751) 2025-12-22T15:03Z [----] followers, [---] engagements "AstraZeneca fronts $100M for Jacobio's pan-KRAS inhibitor $AZN https://www.fiercebiotech.com/biotech/astrazeneca-fronts-100m-jacobios-clinical-stage-pan-kras-inhibitor https://www.fiercebiotech.com/biotech/astrazeneca-fronts-100m-jacobios-clinical-stage-pan-kras-inhibitor" [X Link](https://x.com/TimCarmichael3/status/2003165733476253770) 2025-12-22T18:08Z [----] followers, [---] engagements "Biotechs top [--] stock picks for 2026: analyst. $TERN https://www.fiercebiotech.com/biotech/top-5-stock-picks-biotech-2026-william-blair https://www.fiercebiotech.com/biotech/top-5-stock-picks-biotech-2026-william-blair" [X Link](https://x.com/TimCarmichael3/status/2003570963011764692) 2025-12-23T20:58Z [----] followers, [---] engagements "$CYTK if Aficamten gets approval in nHCM after a positive showing from the ACACIAHCM data then there are likely multiple bidders besides $NVS. Lots of upside left in this one in 2026💥💥💥 $cytk If $nvs can buy $rna at 12B then $CYTK (Mcap around 8B) is not beyond their reach either. There are hardly few derisked assets in market https://t.co/Zo0D1pn2HB $cytk If $nvs can buy $rna at 12B then $CYTK (Mcap around 8B) is not beyond their reach either. There are hardly few derisked assets in market https://t.co/Zo0D1pn2HB" [X Link](https://x.com/TimCarmichael3/status/2003938036925845518) 2025-12-24T21:17Z [----] followers, [----] engagements "Coupang Stock Rallies After Company Says Data Breach Less Severe Than Initially Feared $CPNG https://www.investors.com/news/technology/coupang-stock-data-breach-investigation/ https://www.investors.com/news/technology/coupang-stock-data-breach-investigation/" [X Link](https://x.com/TimCarmichael3/status/2005024690172313759) 2025-12-27T21:15Z [----] followers, [---] engagements "$CPNG looks like risk/reward looks attractive on the upside over the short term💥💥💥 🗓 Watchlist for Mon Dec [--] $GSIT $SKYT $ACOG $XPEV $ZURA $FBRX $LBRX $CPNG $CMTL $ALMU 📌 See pinned tweet for how I use my WL. NFA. https://t.co/TgB2sK9deF 🗓 Watchlist for Mon Dec [--] $GSIT $SKYT $ACOG $XPEV $ZURA $FBRX $LBRX $CPNG $CMTL $ALMU 📌 See pinned tweet for how I use my WL. NFA. https://t.co/TgB2sK9deF" [X Link](https://x.com/TimCarmichael3/status/2005497470470812137) 2025-12-29T04:33Z [----] followers, [---] engagements "$AZN++ one of the best plays in BigBioPharma 💥💥💥 $AZN Cowen Best Ideas 2026: Broad-Based Strengths Poised To Deliver Above Average Growth Buy $AZN has promising new products and pipeline and participates in many large high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth appears to be $AZN Cowen Best Ideas 2026: Broad-Based Strengths Poised To Deliver Above Average Growth Buy $AZN has promising new products and pipeline and participates in many large high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth" [X Link](https://x.com/TimCarmichael3/status/2005620960708473094) 2025-12-29T12:44Z [----] followers, [---] engagements "$ABVX this presentation was likely set up a while back. It would not surprise me if the company had to cancel. BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A dynamics ahead of #JPM26; cross-border M&A under new US tariff rules; and how to approach BPs for a deal. Link👇 https://t.co/ME3eKey568 BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A dynamics ahead of #JPM26;" [X Link](https://x.com/TimCarmichael3/status/2006122754924265758) 2025-12-30T21:58Z [----] followers, [----] engagements "$AXSM++ what a beautiful story💥💥💥 $AXSM Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimers Disease Agitation Axsome Therapeutics Inc. https://t.co/uAJ4OqsFZ2 $AXSM Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimers Disease Agitation Axsome Therapeutics Inc. https://t.co/uAJ4OqsFZ2" [X Link](https://x.com/TimCarmichael3/status/2006380750971752883) 2025-12-31T15:03Z [----] followers, [---] engagements "$AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥 $AZN JP Morgan expects solid AstraZeneca quarter and reassuring outlook https://t.co/w9ihVe6Dot #AZN $AZN JP Morgan expects solid AstraZeneca quarter and reassuring outlook https://t.co/w9ihVe6Dot #AZN" [X Link](https://x.com/TimCarmichael3/status/2008561870857441580) 2026-01-06T15:30Z [----] followers, [---] engagements "$AZN blasting through to a new [--] week high🚀🚀🚀 $AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥 $AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥" [X Link](https://x.com/TimCarmichael3/status/2008567085774106651) 2026-01-06T15:51Z [----] followers, [---] engagements "AZ looks to grow reach in lupus with phase [--] win for self-administered Saphnelo Fierce Pharma. $AZN https://www.fiercepharma.com/pharma/astrazeneca-eyes-leg-lupus-market-phase-3-win-self-administered-saphnelo https://www.fiercepharma.com/pharma/astrazeneca-eyes-leg-lupus-market-phase-3-win-self-administered-saphnelo" [X Link](https://x.com/TimCarmichael3/status/2008626183076728882) 2026-01-06T19:46Z [----] followers, [---] engagements "Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire $CYTK should be standing room only crowd https://stocks.apple.com/AH54WeiwwRoewgb_c-1xfIg https://stocks.apple.com/AH54WeiwwRoewgb_c-1xfIg" [X Link](https://x.com/TimCarmichael3/status/2008680874661867575) 2026-01-06T23:23Z [----] followers, [---] engagements "JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors - January [--] [----] - $AZN $JNJ https://www.zacks.com/stock/news/2812761/jnj-vs-azn-which-drug-stock-comes-out-on-top-for-investors http://Zacks.com https://www.zacks.com/stock/news/2812761/jnj-vs-azn-which-drug-stock-comes-out-on-top-for-investors http://Zacks.com" [X Link](https://x.com/TimCarmichael3/status/2008682284669407641) 2026-01-06T23:29Z [----] followers, [---] engagements "$CYTK++ MS reiterates OW and raises TP to $90 from $71. Look for managements update presentation at J.P. Morgan Healthcare Conference next week💥💥💥💥 $CYTK MS at $90 Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in [----] as commercial names transition $CYTK MS at $90 Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The" [X Link](https://x.com/TimCarmichael3/status/2009257241589748223) 2026-01-08T13:33Z [----] followers, [---] engagements "$AZN++ [----] is shaping up to be another great year Cowen💥💥 $AZN COWEN #Pharma-12 Events In [----] That Could Change Practice Alter Companies Move Stocks-In [----] Pharma has many events with $1B+ potential; here highlight the top [--] (+ one for the pets) and rank them by likelihood to move stocks. $AZN is the only company with three $AZN COWEN #Pharma-12 Events In [----] That Could Change Practice Alter Companies Move Stocks-In [----] Pharma has many events with $1B+ potential; here highlight the top [--] (+ one for the pets) and rank them by likelihood to move stocks. $AZN is the only company with" [X Link](https://x.com/TimCarmichael3/status/2009270755482087433) 2026-01-08T14:27Z [----] followers, [---] engagements "$ATEC++ double top breakout & new [--] week high💥💥💥 "Nobody can predict interest rates the future direction of the economy or the stock market. Dismiss all such forecasts and concentrate on what's actually happening to the companies in which you've invested" Peter Lynch $ATEC criteria: Volume https://t.co/VjAqg7mNyc "Nobody can predict interest rates the future direction of the economy or the stock market. Dismiss all such forecasts and concentrate on what's actually happening to the companies in which you've invested" Peter Lynch $ATEC criteria: Volume https://t.co/VjAqg7mNyc" [X Link](https://x.com/TimCarmichael3/status/2009302964024820137) 2026-01-08T16:35Z [----] followers, [---] engagements "$AZN double top breakout this week along with new [--] week/ all-time high💥💥💥 $AZN++ [----] is shaping up to be another great year Cowen💥💥 $AZN++ [----] is shaping up to be another great year Cowen💥💥" [X Link](https://x.com/TimCarmichael3/status/2009303964710314038) 2026-01-08T16:39Z [----] followers, [---] engagements "Lightning Round: I think you should own Rubrik says Cramer - CNBC $RBRK https://stocks.apple.com/A2_cRuD3WTgCHbZLq588zpA https://stocks.apple.com/A2_cRuD3WTgCHbZLq588zpA" [X Link](https://x.com/TimCarmichael3/status/2009309719895122021) 2026-01-08T17:02Z [----] followers, [---] engagements "$CYTK A very compelling story. TRowe Pricevery smart healthcare investors bought up 20% of the stock. What do you think they know💥💥💥 Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26." [X Link](https://x.com/TimCarmichael3/status/2009628097159504101) 2026-01-09T14:07Z [----] followers, [---] engagements "$SRPT lets see what management has to say at their J.P. Morgan healthcare conference presentation 💥💥💥 $SRPT continues it's march towards $50. https://t.co/CbVYbtxJb1 $SRPT continues it's march towards $50. https://t.co/CbVYbtxJb1" [X Link](https://x.com/TimCarmichael3/status/2009660623710568710) 2026-01-09T16:16Z [----] followers, [---] engagements "$VKTX their day in the sun will come. The data is the data the best safety & efficacy of all the players. Most are confused on whether they bring VK2735 to market alone or sell their position to a large BioPharma. Management knows the value is there as do many holders. How it will play out in [--] is anyones guess. I believe this will be an important year for investors as the $100+billion DiaBesity market continues to expand to more indications and continues to grow. I like the story $VKTX $LLY $NVO The mouth-pieces for the orals that cant hold a candle to Vikings oral will grow louder before" [X Link](https://x.com/TimCarmichael3/status/2010197620560458223) 2026-01-11T03:50Z [----] followers, [----] engagements "$ABVX $LLY dont close the door on this one $LLY remains an extremely well-financed suitor who appears to be well aware of the process in purchasing a French company. They also have the capabilities to manufacture market & provide the scientific support to make a this a successful product launch in Ulcerative Colitiscapabilities $ABVX does not have. Lets get this party started🚀🚀🚀 Huge tells from the $ABVX CEO interview just now. When asked about $LLY meeting with the French Treasury he didnt deny it. Instead he gave us the roadmap: [--]. Confirmed that the FDI (Foreign Direct Investment)" [X Link](https://x.com/TimCarmichael3/status/2010556284488093705) 2026-01-12T03:35Z [----] followers, [----] engagements "Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid $ABVX https://www.wsj.com/health/pharma/abivax-surges-on-report-ely-lily-is-preparing-17-5-billion-bid-119a6fc7st=VXdcDU https://www.wsj.com/health/pharma/abivax-surges-on-report-ely-lily-is-preparing-17-5-billion-bid-119a6fc7st=VXdcDU" [X Link](https://x.com/TimCarmichael3/status/2010690614833057959) 2026-01-12T12:29Z [----] followers, [---] engagements "$VKTX new data looks attractive- looks to be a favorable risk/reward for this small cap gem💥💥 📢 : $VKTX Vikings VK2735 Shows Up to 14.7% Weight Loss in [--] Weeks 👉 : ➤ (NASDAQ: VKTX) publishes Phase [--] results in journal. ➤ achieved up to .% 📢 : $VKTX Vikings VK2735 Shows Up to 14.7% Weight Loss in [--] Weeks 👉 : ➤ (NASDAQ: VKTX) publishes Phase [--] results in journal. ➤ achieved up to .%" [X Link](https://x.com/TimCarmichael3/status/2010716210778828959) 2026-01-12T14:11Z [----] followers, [----] engagements "$TGTX it would be no surprise if the company is putting its $100 mil stock purchase plan to work just as they did the last time it was at these levels. Lets see what CEO MW has to say at the JPM Healthcare Conference. Im sure there will be many interested observers" [X Link](https://x.com/TimCarmichael3/status/2010727979681505400) 2026-01-12T14:58Z [----] followers, [---] engagements "$PFE this management team is clearly the gang that cannot shoot straight & will once again underperform in [----]. I would be surprised if Bourla is still around a year from now. Activist investor Starboard has not seen any return on their $ billion position & will either exit or push for new management. What a sad story. $PFE @AlbertBourla at JPM affirmed Versper [--] results this year Previous Metsera guidance was late [----] and later from Pfizer was q1 [---]. It is [--] months of escalation and [--] monthly. Unfortunately and based on previous [--] and [--] wk data efficacy should be modest and likely" [X Link](https://x.com/TimCarmichael3/status/2010812155256267086) 2026-01-12T20:32Z [----] followers, [---] engagements "$AXSM the easy $$ may have been made but the story remains on solid footing as the venue and earnings continues to ramp up nicely 💥💥💥 $AXSM Total preliminary Q4 and FY'25 net product revenue of $196M and $638M respectively representing 65% and 66% annual growth AUVELITY preliminary FY'25 $507M SUNOSI FY'25 net product rev $124.8M $AXSM Total preliminary Q4 and FY'25 net product revenue of $196M and $638M respectively representing 65% and 66% annual growth AUVELITY preliminary FY'25 $507M SUNOSI FY'25 net product rev $124.8M" [X Link](https://x.com/TimCarmichael3/status/2010813932269609226) 2026-01-12T20:39Z [----] followers, [---] engagements "$ABVX JPM weighs in the potential purchase of Abivax by $LLY and likes the combination 👍 JPM:" Quick Thoughts on $LLY s Reported Interest in Abivax $ABVX ." https://t.co/qI4dkFdiLF JPM:" Quick Thoughts on $LLY s Reported Interest in Abivax $ABVX ." https://t.co/qI4dkFdiLF" [X Link](https://x.com/TimCarmichael3/status/2011101096790671554) 2026-01-13T15:40Z [----] followers, [----] engagements "$AZN AstraZeneca brings Modella AI in-house to power oncology R&D $AZN https://t.co/Iq3XLH1a08 AstraZeneca brings Modella AI in-house to power oncology R&D $AZN https://t.co/Iq3XLH1a08" [X Link](https://x.com/TimCarmichael3/status/2011300988339318872) 2026-01-14T04:54Z [----] followers, [---] engagements "$TGTX the growth story remains intact. Can we please get a little more respect from investorsplease🙏 $TGTX Preliminary total global full year [----] revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year [----] net product revenue of approximately $182 million and $594 million respectively Full Year [----] target total global revenue of $TGTX Preliminary total global full year [----] revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year [----] net product revenue of approximately $182 million and $594 million respectively Full" [X Link](https://x.com/TimCarmichael3/status/2011302416822800457) 2026-01-14T05:00Z [----] followers, [---] engagements "FDA approves AZ/Daiichi's Enhertu in 1st-line HER2 breast cancer $AZN https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyo-score-fda-nod-enhertu-combo-breast-cancer https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyo-score-fda-nod-enhertu-combo-breast-cancer" [X Link](https://x.com/TimCarmichael3/status/2011432938227818938) 2026-01-14T13:39Z [----] followers, [----] engagements "$AZN the momentum continues to ramp in [----]. Hard to find anyone in BigBioPharma with a story like this💥💥💥 $AZN #JPM26 [--] positive phase [--] readouts since [----] with another [---] phase [--] trials to readout $AZN #JPM26 [--] positive phase [--] readouts since [----] with another [---] phase [--] trials to readout" [X Link](https://x.com/TimCarmichael3/status/2011434594520981782) 2026-01-14T13:45Z [----] followers, [---] engagements "$TGTX JPM reiterated BUY $49 PT raising earnings & revenue estimates 💥💥 $TGTX JP BUY PT$49 #JPM26 Briumvi US sales 4Q beat; Focus on [----] guidance. 4Q US Briumvi sales were $182mn (+19% q/q) which came in above JPMe $177mn. Initial FY26 total WW guidance of $875-900mn comprised of $825-850mn Briumvi US net sales. Mgmt noted that [----] q/q cadence $TGTX JP BUY PT$49 #JPM26 Briumvi US sales 4Q beat; Focus on [----] guidance. 4Q US Briumvi sales were $182mn (+19% q/q) which came in above JPMe $177mn. Initial FY26 total WW guidance of $875-900mn comprised of $825-850mn Briumvi US net sales. Mgmt" [X Link](https://x.com/TimCarmichael3/status/2011512290076753973) 2026-01-14T18:54Z [----] followers, [---] engagements "AZ's $80B revenue target 'very much within reach' CFO says $AZN https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says" [X Link](https://x.com/TimCarmichael3/status/2011517870564340003) 2026-01-14T19:16Z [----] followers, [---] engagements "Costco Executives Have Been Selling Stock on the Heels of a Rough [----] - Barron's. $COST https://www.barrons.com/articles/costco-execs-stock-sales-f9e586cc https://www.barrons.com/articles/costco-execs-stock-sales-f9e586cc" [X Link](https://x.com/TimCarmichael3/status/2011671429436018782) 2026-01-15T05:26Z [----] followers, [--] engagements "$OCUL $SNY speculation of buyout offer #LaLettre: $SNY makes fresh play for $OCUL. The French pharmaceutical group and its chief executive Paul Hudson are preparing an improved bid to acquire the US biotech start-up. Its initial offer of$16 per share was rejected by the US biotech's board. https://t.co/REAR4tEG6X #LaLettre: $SNY makes fresh play for $OCUL. The French pharmaceutical group and its chief executive Paul Hudson are preparing an improved bid to acquire the US biotech start-up. Its initial offer of$16 per share was rejected by the US biotech's board. https://t.co/REAR4tEG6X" [X Link](https://x.com/TimCarmichael3/status/2011782551497478255) 2026-01-15T12:48Z [----] followers, [---] engagements "JPM26 Day 3: AbbVie touts 'clear line of sight' to continued growth into 2030s Fierce Pharma $ABBV https://www.fiercepharma.com/pharma/fierce-pharmas-jpm26-tracker-day-3 https://www.fiercepharma.com/pharma/fierce-pharmas-jpm26-tracker-day-3" [X Link](https://x.com/TimCarmichael3/status/2011862889196368098) 2026-01-15T18:07Z [----] followers, [---] engagements "TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally. TGTX https://stocktwits.com/news-articles/markets/equity/tgtx-stock-pops-as-briumvi-boom-reignites-bull-case-goldman-sachs-sees-room-for-32-rally/cmU1fZAR470 https://stocktwits.com/news-articles/markets/equity/tgtx-stock-pops-as-briumvi-boom-reignites-bull-case-goldman-sachs-sees-room-for-32-rally/cmU1fZAR470" [X Link](https://x.com/TimCarmichael3/status/2011975827852783733) 2026-01-16T01:36Z [----] followers, [---] engagements "$VKTX this one is like a coiled spring that will snap to the upside when people least expect it. Every large BioPharma absolutely knows that DiaBesity is the $150+ Billion market where they must have a LEGITIMATE presence. Dont sell this $3.5 billion small cap shortthe risk/reward upside is substantial 💥💥💥 $GPCR hit $90 in after hours trading session 😍😍 Recall stock price was bearish for a long time Market cycle frustrates many investors and traders followed by a huge rally $VKTX has all the ingredients too for a successful comeback and it will. Own $VKTX & $GPCR Obesity $GPCR hit $90 in" [X Link](https://x.com/TimCarmichael3/status/2011979980771672201) 2026-01-16T01:53Z [----] followers, [----] engagements "$VKTX CEO BL is anything but shy. I would rather say strategic as he is a Wall Street guy who knows how the game is played. Rather than sellout early hes made the decision to shepherd VK2735 through the clinical trialsknowing that hes creating more value along the way. There are numerous major players who would like to buy them but hes not a seller until he can get the price he wants. There remains a lot of upside if anyone has any patience💥💥 @Pharmdca $VKTX has a shy CEO who clearly not helping company PR ( although executing great at progressing assets ) Long term good drugs will prevail" [X Link](https://x.com/TimCarmichael3/status/2011982769153310940) 2026-01-16T02:04Z [----] followers, [----] engagements "$TGTX risk/reward outlook through [----] looks to be quite favorable. The BRIUMVI franchise continues to accelerate & revenues cash flow & EPS remains on the upswing. Dont give up on this small cap gem💥💥💥 $TGTX TG is at an inflection point where for the next few years there will be meaningful cash flows even with the subQ Briumvi launch. estimate $400-$700M in annual cash flow in next few years increasing to $900M-$1B by [----]. $TGTX TG is at an inflection point where for the next few years there will be meaningful cash flows even with the subQ Briumvi launch. estimate $400-$700M in annual" [X Link](https://x.com/TimCarmichael3/status/2012158211454099554) 2026-01-16T13:41Z [----] followers, [---] engagements "$CPNG Deutsche Bank upgraded to BUY saying that most of the regulatory uncertainties have been priced in $CPNG looks super compelling here already filled some gaps now bouncing off VWAPs and trendlines from the [----] lows. there were also some block trades on the tape yesterday that suggest some big buyers are starting to accumulate. $CPNG trading below 18x [----] EV/EBITDA with https://t.co/BBYIEODyQA $CPNG looks super compelling here already filled some gaps now bouncing off VWAPs and trendlines from the [----] lows. there were also some block trades on the tape yesterday that suggest some big" [X Link](https://x.com/TimCarmichael3/status/2012159689887256718) 2026-01-16T13:47Z [----] followers, [---] engagements "$MMM BofA TOP PICK raise PT $200/sh. We expect a Q beat on 1/20 and see better growth performance driven by self help initiatives" [X Link](https://x.com/TimCarmichael3/status/2012164814265545197) 2026-01-16T14:07Z [----] followers, [---] engagements "$RBRK [----] looks to be a very good year. Risk/reward looks quite favorable from current levels💥💥 $RBRK stock is now back to pre-Q3 levels. Meanwhile: 🔹Subscription revenue grew 52% 🔹Free cash flow is up +347% 🔹Net retention is 120% A great business at a very reasonable price in my opinion. https://t.co/A2Q1qxBfEg $RBRK stock is now back to pre-Q3 levels. Meanwhile: 🔹Subscription revenue grew 52% 🔹Free cash flow is up +347% 🔹Net retention is 120% A great business at a very reasonable price in my opinion. https://t.co/A2Q1qxBfEg" [X Link](https://x.com/TimCarmichael3/status/2012170445894648054) 2026-01-16T14:29Z [----] followers, [---] engagements "$AZN $ASML $RHBBY - all [--] are powering the European markets 💥 Here are the top holdings in $EFA iShares MSCI EAFE ETF: 🥇 ASML Holding $ASML 2.3% 🥈 AstraZeneca $AZN 1.4% 🥉 Roche Holding $ROG 1.4% https://t.co/cMnbwFV4bI Here are the top holdings in $EFA iShares MSCI EAFE ETF: 🥇 ASML Holding $ASML 2.3% 🥈 AstraZeneca $AZN 1.4% 🥉 Roche Holding $ROG 1.4% https://t.co/cMnbwFV4bI" [X Link](https://x.com/TimCarmichael3/status/2012998074566656144) 2026-01-18T21:18Z [----] followers, [---] engagements "JPM26: Biotechs M&A lift the new Biogen and Mercks $70B target BioPharma Dive $BGEN $MRK $SMMT https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/ https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/" [X Link](https://x.com/TimCarmichael3/status/2013606722082889934) 2026-01-20T13:37Z [----] followers, [---] engagements "$ABVX games people play $ABVX Abivax CEO dismisses noise around rumored $LLY bid. "There was no discussion on the acquisition of Abivax. . if there was a conversation this would be illegal." https://t.co/p3VfkSmodA $ABVX Abivax CEO dismisses noise around rumored $LLY bid. "There was no discussion on the acquisition of Abivax. . if there was a conversation this would be illegal." https://t.co/p3VfkSmodA" [X Link](https://x.com/TimCarmichael3/status/2013633139474579889) 2026-01-20T15:22Z [----] followers, [---] engagements "AstraZeneca pens $630M pact for remaining China rights to CAR-T. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t" [X Link](https://x.com/TimCarmichael3/status/2014002891976040529) 2026-01-21T15:51Z [----] followers, [---] engagements "$MRNA BofA king putz ANALyst Stranahan reits his UNDERPERFORM $27 PT today. I guess stock performance (+60% past month) means nothing. Makes you wonder how a clown like this gets a paycheck. $MRNA +15% today on strong cancer vaccine data Moderna is ripping higher after new long-term data showed its personalized cancer vaccine used together with $MRKs Keytruda continues to deliver meaningful benefits. Key takeaway: - The Moderna + Merck combo cut the risk of https://t.co/Q6z0uuKlTX $MRNA +15% today on strong cancer vaccine data Moderna is ripping higher after new long-term data showed its" [X Link](https://x.com/TimCarmichael3/status/2014370257750605852) 2026-01-22T16:11Z [----] followers, [---] engagements "Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's $MRNA BofA reiterate UNDERPERFORM $27 PT https://www.barrons.com/articles/moderna-stock-rally-cancer-vaccine-study-merck-2ae374ae https://www.barrons.com/articles/moderna-stock-rally-cancer-vaccine-study-merck-2ae374ae" [X Link](https://x.com/TimCarmichael3/status/2014548853899280718) 2026-01-23T04:00Z [----] followers, [---] engagements "Sanofi posts mixed phase [--] data on key eczema prospect $ SNY https://www.fiercebiotech.com/biotech/sanofi-posts-mixed-phase-3-data-key-eczema-prospect-plans-global-filings https://www.fiercebiotech.com/biotech/sanofi-posts-mixed-phase-3-data-key-eczema-prospect-plans-global-filings" [X Link](https://x.com/TimCarmichael3/status/2014748508411081186) 2026-01-23T17:14Z [----] followers, [---] engagements "Novo's Wegovy pill launch wows with strong early uptake: analysts $NVO https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says" [X Link](https://x.com/TimCarmichael3/status/2014751484823646459) 2026-01-23T17:26Z [----] followers, [---] engagements "$VKTX lots of triggers on the horizon in [----] getting ready for PRIME TIME💥💥💥 $VKTX OPPY hosted CEO Brian Lian &new CCO Neil Aubuchon for a group call discussing recent progress and key catalysts ahead. Neil highlighted promising profiles of both subQ and oral VK2735 and views VKTX's unique setting having both subQ and oral formulations as an important $VKTX OPPY hosted CEO Brian Lian &new CCO Neil Aubuchon for a group call discussing recent progress and key catalysts ahead. Neil highlighted promising profiles of both subQ and oral VK2735 and views VKTX's unique setting having both subQ" [X Link](https://x.com/TimCarmichael3/status/2014827196548800828) 2026-01-23T22:26Z [----] followers, [----] engagements "$SRPT lets see what the company has to say on their Monday call $SRPT For a long time the loudest claim has been that Elevidys doesnt work. But parents keep showing up again and again to defend this therapy unprompted unpaid and with nothing to gain. People dont do that for something that doesnt work https://t.co/AhNrWvEZ5M $SRPT For a long time the loudest claim has been that Elevidys doesnt work. But parents keep showing up again and again to defend this therapy unprompted unpaid and with nothing to gain. People dont do that for something that doesnt work https://t.co/AhNrWvEZ5M" [X Link](https://x.com/TimCarmichael3/status/2015559121467068780) 2026-01-25T22:55Z [----] followers, [---] engagements "$SRPT $SRPT Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients https://t.co/ZnVCNYjcNt $SRPT Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients https://t.co/ZnVCNYjcNt" [X Link](https://x.com/TimCarmichael3/status/2015778591267528864) 2026-01-26T13:27Z [----] followers, [---] engagements "Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys - Barrons. $SRPT https://stocks.apple.com/AOJRgK3tEQ4Kv0JFuo16OfA https://stocks.apple.com/AOJRgK3tEQ4Kv0JFuo16OfA" [X Link](https://x.com/TimCarmichael3/status/2015812910094618987) 2026-01-26T15:43Z [----] followers, [---] engagements "Sarepta battling slowing sales claims Duchenne gene therapys impact grows with time BioPharma Dive. $SRPT https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/ https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/" [X Link](https://x.com/TimCarmichael3/status/2015851653098861033) 2026-01-26T18:17Z [----] followers, [---] engagements "@stocktilludrop @mikegoodma If you invest in growth stocks you invest in growing companies. $GILDs pipe is uninspiring" [X Link](https://x.com/TimCarmichael3/status/692902437405990912) 2016-01-29T02:49Z [----] followers, [--] engagements "@SellSideSource WOW ---- I call that "leading edge research" Surprised GS even noticed --- though did recommend that $ALXN spend $8.4 Billion on $GEVA ---- excellent due diligence there" [X Link](https://x.com/TimCarmichael3/status/974269988377890817) 2018-03-15T13:04Z [----] followers, [--] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@TimCarmichael3 Tim Carmichael
Tim Carmichael posts on X about $azn, $vktx, $cytk, $lly the most. They currently have [-----] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.
Engagements: [---] #
- [--] Week [-----] -59%
- [--] Month [------] +68%
- [--] Months [-------] +187%
- [--] Year [-------] +32%
Mentions: [--] #
- [--] Week [--] -41%
- [--] Month [---] +36%
- [--] Months [---] +172%
- [--] Year [---] +33%
Followers: [-----] #
- [--] Week [-----] +0.59%
- [--] Month [-----] +1.50%
- [--] Months [-----] +9.70%
- [--] Year [-----] +27%
CreatorRank: [---------] #
Social Influence
Social category influence stocks 64.29% finance 23.57% currencies 17.14% technology brands 2.86% exchanges 2.14% cryptocurrencies 2.14% countries 1.43% travel destinations 0.71% celebrities 0.71% gaming 0.71%
Social topic influence $azn #135, $vktx #43, $cytk 8.57%, $lly #57, $abvx 7.86%, $tgtx 5.71%, $srpt 5%, strong 5%, flow 5%, ceo 5%
Top accounts mentioned or mentioned by @biopharmadive @troutandchar @apexonco @cordenpharma @wustlbear @albertbourla @pharmdca @stocktilludrop @mikegoodma @sellsidesource @biopharmiq @lng_investor_ @justin_mcd01 @prosperousguy
Top assets mentioned AstraZeneca PLC (AZN) Viking Therapeutics, Inc (VKTX) Cytokinetics Inc. (CYTK) Eli Lilly and Company (LLY) Abivax SA (ABVX) TG Therapeutics, Inc. (TGTX) Sarepta Therapeutics, Inc. (SRPT) Bristol-Myers Squibb Co (BMY) Rubrik, Inc. (RBRK) Novo-Nordisk (NVO) Pfizer, Inc. (PFE) Disc Medicine, Inc. Common Stock (IRON) Astronics Corp (ATRO) Axsome Therapeutics, Inc (AXSM) Merck & Co., Inc. (MRK) 3M Co (MMM) Ocular Therapeutix, Inc. (OCUL) CoreWeave, Inc (CRWV) Coupang, Inc. (CPNG) Janux Therapeutics, Inc. (JANX) Novartis AG (NVS) Oracle Corporation (ORCL) AbbVie Inc (ABBV) Viking Holdings Ltd (VIK) Structure Therapeutics Inc. (GPCR) Morgan Stanley (MS) Sanofi (SNY) Synthetify (SNY) Applied Digital Corp. (APLD) Goldman Sachs (GS) Edgewise Therapeutics, Inc. (EWTX) Moderna Inc (MRNA) BridgeBio Pharma, Inc. Common Stock (BBIO) Eaton Corporation PLC (ETN) Electroneum (ETN) Insmed, Inc. (INSM) Acadia Pharmaceuticals Inc. (ACAD) Jazz Pharmaceuticals, Inc. (JAZZ) Joby Aviation, Inc. (JOBY) Seagen Inc (SGEN) Bitcoin (BTC) Strategy (MSTR) BioMarin Pharmaceutical, Inc. (BMRN)
Top Social Posts
Top posts by engagements in the last [--] hours
"$VKTX++ getting FDA approval to skip a trial phase & move directly into Phase [--] significantly accelerates their development time in the GLP1 market. Lots to like here in this small cap obesity play. Accelerating timelines should increase the pressure on the HUGE short position betting against VK2735. This has the makings of a potential powder keg 🚀🚀🚀 https://twitter.com/i/web/status/2021941537899151517 https://twitter.com/i/web/status/2021941537899151517"
X Link 2026-02-12T13:36Z [----] followers, [----] engagements
"$IRON two months ago it was an overreaction . Today it was a heart piercing CRL Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://t.co/WzW3kfHAgk Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://t.co/WzW3kfHAgk"
X Link 2026-02-13T21:29Z [----] followers, [---] engagements
"Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy Sarepta Therapeutics Inc. $SRPT https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-report-3-year-topline-data-embark-study"
X Link 2026-01-23T22:37Z [----] followers, [---] engagements
"VKTX Stock Rallies After Hours On Optimism Around Companys Obesity Pipeline. $VKTX https://stocktwits.com/news-articles/markets/equity/vktx-stock-rallies-after-hours-on-optimism-around-companys-obesity-portfolio/cZb6MYxR4Ak https://stocktwits.com/news-articles/markets/equity/vktx-stock-rallies-after-hours-on-optimism-around-companys-obesity-portfolio/cZb6MYxR4Ak"
X Link 2026-02-11T23:46Z [----] followers, [---] engagements
"BridgeBio scores with dwarfism drug setting up showdown with BioMarin Ascendis via @BioPharmaDive. $BBIO https://www.biopharmadive.com/news/bridgebio-dwarfism-drug-data-infigratinib-achondroplasia-biomarin-ascendis/812034/ https://www.biopharmadive.com/news/bridgebio-dwarfism-drug-data-infigratinib-achondroplasia-biomarin-ascendis/812034/"
X Link 2026-02-12T13:22Z [----] followers, [---] engagements
"Disc Medicine Stock Slides After FDA Fast-Track Approval Doubts Surface Wall Street Calls It An Overreaction. $IRON https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd https://stocktwits.com/news-articles/markets/equity/disc-medicine-stock-slides-after-fda-fast-track-approval-doubts-surface/cLe0e2PREtd"
X Link 2025-12-22T02:56Z [----] followers, [---] engagements
"Astronics Corporation Announces Preliminary Unaudited Revenue for Fourth Quarter [----] and Initiates Revenue Guidance for [----] - Business Wire $ATRO https://stocks.apple.com/ArSUKm62KQTOAjE1ybLXOlA https://stocks.apple.com/ArSUKm62KQTOAjE1ybLXOlA"
X Link 2026-01-08T14:58Z [----] followers, [---] engagements
"$ETN US Senator on Energy Committee buying stock think he knows anything PENDING BREAKING: Senator John Hickenlooper filed a purchase of up to $100000 of stock in Eaton Corporation. Eaton is a power management company. Hickenlooper sits on the Senate Committee on Energy. We'll be keeping an eye on $ETN. https://t.co/S1l1yDnQCF BREAKING: Senator John Hickenlooper filed a purchase of up to $100000 of stock in Eaton Corporation. Eaton is a power management company. Hickenlooper sits on the Senate Committee on Energy. We'll be keeping an eye on $ETN. https://t.co/S1l1yDnQCF"
X Link 2026-02-10T03:01Z [----] followers, [---] engagements
"$IRON good thing they did a $250 million stock offering at $84 share [--] months ago $IRON two months ago it was an overreaction . Today it was a heart piercing CRL $IRON two months ago it was an overreaction . Today it was a heart piercing CRL"
X Link 2026-02-13T21:39Z [----] followers, [---] engagements
"Wall Street eyes upside for Insmed after Brinsupri sales beat $INSM https://www.fiercepharma.com/pharma/insmed-blowout-brinsupri-sales-beat-fuels-multi-blockbuster-outlook https://www.fiercepharma.com/pharma/insmed-blowout-brinsupri-sales-beat-fuels-multi-blockbuster-outlook"
X Link 2026-01-09T20:37Z [----] followers, [---] engagements
"$AXSM a wonderful mid cap story with a dynamic product portfolio. This one is certainly on the M&A screens at BigBioPharma 💥💥💥 Piper Sandler $AXSM's PT to $223 from $148 reiterated at an Overweight and said 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Piper Sandler Additionally said: We met with Axsome senior management recently and gained more insights into commercial dynamics Piper Sandler $AXSM's PT to $223 from $148 reiterated at an Overweight and said 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Piper Sandler Additionally said: We met with Axsome senior"
X Link 2026-01-16T15:31Z [----] followers, [---] engagements
"$JANX thank goodness they were able to raise $350 million at $63 sh [--] weeks ago only to turn back into a pre-teenager almost overnight. Lots of bag holders still in this name (luckily not me)"
X Link 2026-01-22T17:37Z [----] followers, [---] engagements
"Bristol Myers buys into Januxs masked T cell engagers BioPharma Dive $JANX $BMY https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/ https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/"
X Link 2026-01-22T18:28Z [----] followers, [---] engagements
"$TGTX strong retention rates for BRIUMVI lock for a strong [----] $TGTX important observation occurring-Retention &Duration - recent social media checks showing large numbers of #Bruimvi patients on therapy now [--] years [--] yrs even [--] years - with no new lesions or relapses - many quoting best they ever felt - patients switching to BRIUMVI are $TGTX important observation occurring-Retention &Duration - recent social media checks showing large numbers of #Bruimvi patients on therapy now [--] years [--] yrs even [--] years - with no new lesions or relapses - many quoting best they ever felt - patients"
X Link 2026-01-25T22:05Z [----] followers, [---] engagements
"Joby Aviation Stock Plunges. This Is Why. $JOBY https://www.barrons.com/articles/joby-aviation-stock-electric-taxi-3ee74440st=6yoxad https://www.barrons.com/articles/joby-aviation-stock-electric-taxi-3ee74440st=6yoxad"
X Link 2026-01-29T15:03Z [----] followers, [---] engagements
"$TGTX dont overlook this solid growth story💥💥💥 B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note: https://t.co/pf2vEhV78g B Riley reiterated $TGTX Buy/$55. $NVS $RHHBY Here's what B Riley had to say in its note: https://t.co/pf2vEhV78g"
X Link 2026-02-04T13:12Z [----] followers, [---] engagements
"$PFE any meaningful update on the $43 billion $SGEN acquisition I see impairment charges but no cartwheels on how great things are going there. $PFE management continues to be a disaster. $PFE MGT yesterday excited about GLP1+ amylin combo ( still on phase 1) potential BIC . look at early phase [--] with small doses how nausea / vomit are synergistic. Tiny doses of Met097 ( [---] ) and [---] ( o.3) in combo result in nausea and vomit while higher doses of each alone ( https://t.co/dh4Q9tbCbR $PFE MGT yesterday excited about GLP1+ amylin combo ( still on phase 1) potential BIC . look at early phase 1"
X Link 2026-02-04T13:28Z [----] followers, [---] engagements
"$VKTX lets see if management can give shareholders a little love. Theres a lot of value in this small cap gem will it ever be unlockedit sure looks like its undervalued 💥💥💥 Viking Therapeutics to Report Financial Results for Second Quarter [----] on July [--] [----] https://t.co/GhRAixNfhJ Viking Therapeutics to Report Financial Results for Second Quarter [----] on July [--] [----] https://t.co/GhRAixNfhJ"
X Link 2026-02-05T05:16Z [----] followers, [----] engagements
"Bristol Myers Stock Rises. Why Fourth-Quarter Earnings Are Exciting Investors. https://www.barrons.com/articles/bristol-myers-earnings-stock-price-8a5e147cst=oyMCqr https://www.barrons.com/articles/bristol-myers-earnings-stock-price-8a5e147cst=oyMCqr"
X Link 2026-02-05T12:30Z [----] followers, [---] engagements
"$AZN do you do any fact checking before you comment AZN just changed the listing to the NYSE from OTC ADS. Do you use a computer It's amazing how much AZN stock popped Monday and equally amazing that it held most of the 100%-plus gain Tuesday. https://t.co/lWXtYyCQ72 It's amazing how much AZN stock popped Monday and equally amazing that it held most of the 100%-plus gain Tuesday. https://t.co/lWXtYyCQ72"
X Link 2026-02-06T16:02Z [----] followers, [----] engagements
"$EIKN what a joke Who ran the books on this POS How embarrassing. $EIKN prices at $18/share to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI $EIKN prices at $18/share to raise $381m at a $972m market cap. Here's @ApexOnco on what this IPO tells us: https://t.co/OYpmTI21qI"
X Link 2026-02-06T16:08Z [----] followers, [---] engagements
"$ORCL downgrade $ORCL : Melius downgrades to sets $ Analyst flags weak cash generation AI monetization uncertainty and sees limited upside as value may be absorbed by debt and dilution https://t.co/vaCwWmW2tW $ORCL : Melius downgrades to sets $ Analyst flags weak cash generation AI monetization uncertainty and sees limited upside as value may be absorbed by debt and dilution https://t.co/vaCwWmW2tW"
X Link 2026-02-09T16:27Z [----] followers, [---] engagements
"$RBRK after last Q results company raised guidance significantlypushing stock back into $90s. Upcoming results could force a MAJOR short covering rally as the fundamentals remain very compelling in the cybersecurity space. Risk/reward for both traders and investors looks VERY ATTRACTIVE at current levels on this small cap beauty💥💥💥💥 $RBRK had its best checks in +5 years with a competitor's issues mainly idiosyncratic. Expecting +10% sales / 2% ARR upside though stock will likely trade on FY27 initial guide primarily where our math implies $1.8B ARR and low-20s sales growth - Piper $RBRK"
X Link 2026-02-10T05:14Z [----] followers, [---] engagements
"$AZN ++ what a powerhouse $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative"
X Link 2026-02-10T12:20Z [----] followers, [---] engagements
"AstraZeneca's oral GLP-1 scored phase [--] wins but no data yet $AZN https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data https://www.fiercebiotech.com/biotech/astrazeneca-reveals-oral-glp1-scored-phase-2-wins-holds-back-weight-loss-data"
X Link 2026-02-10T17:31Z [----] followers, [----] engagements
"AZ sets sights on 25+ blockbusters by [----] $AZN https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition"
X Link 2026-02-10T17:57Z [----] followers, [---] engagements
"AZ sets sights on 25+ blockbusters by [----]. $AZN https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition https://www.fiercepharma.com/pharma/astrazeneca-sets-sights-25-blockbusters-2030-fuel-80b-revenue-ambition"
X Link 2026-02-10T21:53Z [----] followers, [---] engagements
"Strategys Michael Saylor Doubles Down on Bitcoin. Wall Street Is Shorting the Stock. $MSTR https://www.barrons.com/articles/strategy-stock-price-bitcoin-short-interest-michael-saylor-mstr-9e6f5c83st=8hnzCE https://www.barrons.com/articles/strategy-stock-price-bitcoin-short-interest-michael-saylor-mstr-9e6f5c83st=8hnzCE"
X Link 2026-02-10T23:17Z [----] followers, [---] engagements
"AstraZeneca Teases Very Competitive Weight-Loss PillBut Stays Mum on Details - BioSpace. $AZN https://www.biospace.com/business/astrazeneca-teases-very-competitive-weight-loss-pill-but-stays-mum-on-details https://www.biospace.com/business/astrazeneca-teases-very-competitive-weight-loss-pill-but-stays-mum-on-details"
X Link 2026-02-11T16:39Z [----] followers, [---] engagements
"$AZN ++ new [--] week & all-time high 💥💥💥 $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative $AZN Having delivered [--] positive Phase III read outs last year $AZN indicated that it has more than [---] ongoing late-stage trials with over [--] expected to report results in [----]. Soriot noted that "a substantial and growing number" of these feature "transformative"
X Link 2026-02-11T20:01Z [----] followers, [---] engagements
"$VKTX ++ this story is starting to ramp nicely [----] looks to be a nice year for investor returns.💥💥 $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY $VKTX in less then [--] months $VKTX completed enrollment on both its PHASE [--] trials for SUBq - enrollment rates as fast $LLY"
X Link 2026-02-11T23:08Z [----] followers, [---] engagements
"$BMRN one of the top boring biotech of all-time. Nobody would ever step up and buy this company & put it out of investors memory. I held $BMRN for over [--] years thinking it was a no brainer takeover at some point (sold it last year) Funny that they now are a buyer deal actually make lots of sense and the stock should be up today I held $BMRN for over [--] years thinking it was a no brainer takeover at some point (sold it last year) Funny that they now are a buyer deal actually make lots of sense and the stock should be up today"
X Link 2025-12-19T13:31Z [----] followers, [---] engagements
"$VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in [----]. Remember that many large BioPharmas dont have representation in the $150+ billion Diabesity market - the largest market out there. $ABBV $MRK $BMY and others could EASILY write a $10 billion check to get the best science on the cusp of PRIMETIME. They already have infrastructure-R&D manufacturing marketing and could drop VK2735 right into their product portfolio. This"
X Link 2026-02-05T21:03Z [----] followers, 11.4K engagements
"$VKTX++ this one is starting to ramp up - look for [----] to be a fruitful year for shareholders 💥💥 $VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in [----]. Remember that many large BioPharmas dont have $VKTX when this little obesity small cap play gets to the mid-$20s it has proven to be a 50% type return when the speculative juices start to flow. Dont have much clarity on the timing but it could easily be sometime in 2026."
X Link 2026-02-11T23:16Z [----] followers, [----] engagements
"$VKTX $VKTX $LLY $NVO 🚨 EARNINGS CALL SIGNAL VIKING THERAPEUTICS LEADERSHIP SPECIFIES THAT THEIR AGREEMENT WITH API/FINISH/FILL PARTNER @cordenpharma IS FULLY TRANSFERABLE $VKTX $LLY $NVO 🚨 EARNINGS CALL SIGNAL VIKING THERAPEUTICS LEADERSHIP SPECIFIES THAT THEIR AGREEMENT WITH API/FINISH/FILL PARTNER @cordenpharma IS FULLY TRANSFERABLE"
X Link 2026-02-12T03:58Z [----] followers, [---] engagements
"$VKTX ++ What the analysts not highlighting from $LLY Attain -maintain statement that Gi AEs were C/W with other incretins. Unless lilly employs very sloppy top line writer it suggests 15-30 % vomit rate when switching from tirzepatide to orforglipron despite likely slow What the analysts not highlighting from $LLY Attain -maintain statement that Gi AEs were C/W with other incretins. Unless lilly employs very sloppy top line writer it suggests 15-30 % vomit rate when switching from tirzepatide to orforglipron despite likely slow"
X Link 2026-02-12T13:21Z [----] followers, [---] engagements
"Anthropic closes $30 billion funding round as cash keeps flowing into top AI startups https://cnb.cx/46NqyN3 https://cnb.cx/46NqyN3"
X Link 2026-02-12T20:14Z [----] followers, [--] engagements
"Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://stocks.apple.com/AiQlbBBKpQTawPwfuoDGNXA https://stocks.apple.com/AiQlbBBKpQTawPwfuoDGNXA"
X Link 2026-02-12T20:24Z [----] followers, [---] engagements
"$MMM++ new [--] week high & highest value over last [--] years. Beware the talking head💥💥💥 Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://t.co/GlEkksBC3P Trade Tracker: Stephanie Link sells 3M - CNBC $MMM up [--] points in a week since then💥💥 https://t.co/GlEkksBC3P"
X Link 2026-02-12T20:29Z [----] followers, [---] engagements
"Coatue founder Philippe Laffont: The world is moving to the token economy https://cnb.cx/4rSPkDS https://cnb.cx/4rSPkDS"
X Link 2026-02-13T23:08Z [----] followers, [--] engagements
"$VKTX $CYTK $TGTX #JPM2026 The JPMorgan Healthcare Conference is just around the corner and takes place in SF from January 12-15 [----] and is the largest gathering of healthcare companies executives and investors in the world. The conference has annually served as an event where M&A fireworks take place with many deals both big and small taking place. Stay tuned it promises to an exciting conference for investors.💥💥💥💥"
X Link 2025-12-04T20:38Z [----] followers, [----] engagements
"$RBRK over [----] million shares sold short🚀🚀 $RBRK++ solid Q great earning& revenues raising forward guidancemiss to investors ears $RBRK++ solid Q great earning& revenues raising forward guidancemiss to investors ears"
X Link 2025-12-04T21:24Z [----] followers, [---] engagements
"$VKTX++ hope springs eternal Still [--] million shares sold short & betting against VK2735💥💥💥 $VKTX FDA Pathway Catalyst Incoming The Real Catalyst Nobodys Talking About Everyones staring at charts while the actual event that could reprice Viking overnight is happening right under the radar: The FDA meeting on the ORAL VK2735 pathway. Heres the deal: $VKTX FDA Pathway Catalyst Incoming The Real Catalyst Nobodys Talking About Everyones staring at charts while the actual event that could reprice Viking overnight is happening right under the radar: The FDA meeting on the ORAL VK2735 pathway."
X Link 2025-12-04T22:42Z [----] followers, [----] engagements
"$RBRK++ visibility has increased company guidance bullish $RBRK Rubrik Inc. (RBRK) Analyst Price Targets https://t.co/kM0NsjPta7 $RBRK Rubrik Inc. (RBRK) Analyst Price Targets https://t.co/kM0NsjPta7"
X Link 2025-12-05T14:16Z [----] followers, [---] engagements
"Praxis soars higher; Bristol Myers CAR-T therapy wins broader use via @BioPharmaDive https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-12-05%20BioPharma%20Dive%20%5Bissue:79517%5D&utm_term=BioPharma%20Dive https://www.biopharmadive.com/news/praxis-denali-breyanzi-kelun-crescent-astrazeneca-neurimmune/807098/utm_source=Sailthru&utm_medium=email&utm_campaign=Issue:%202025-12-05%20BioPharma%20Dive%20%5Bissue:79517%5D&utm_term=BioPharma%20Dive"
X Link 2025-12-05T16:51Z [----] followers, [---] engagements
"$TER story remains on solid footing & new players like Stifel continue to gravitate to the company. New [--] week high💥💥 $TER Upgrading Teradyne to Buy: Narrative shift revenue shift and +optionality in AI compute too important to ignore https://t.co/BTAsOlbf0k $TER Upgrading Teradyne to Buy: Narrative shift revenue shift and +optionality in AI compute too important to ignore https://t.co/BTAsOlbf0k"
X Link 2025-12-05T18:05Z [----] followers, [---] engagements
"$OCUL $OCUL JMP BUY PT $29 new regulatory strategy could get Axpaxli approved at least a year earlier than previously anticipated&make it first long- acting TKI available to wet AMD patients.This is a bold move with limited downside in our view as $OCUL could simply resubmit a more $OCUL JMP BUY PT $29 new regulatory strategy could get Axpaxli approved at least a year earlier than previously anticipated&make it first long- acting TKI available to wet AMD patients.This is a bold move with limited downside in our view as $OCUL could simply resubmit a more"
X Link 2025-12-08T01:54Z [----] followers, [---] engagements
"$SRPT ++ hair on this dog but an outstanding speculation on a risk/reward play💥💥💥 Agree - $SRPT is my second largest long. It will rip back to $50. One of the Most Misunderstood Biotechs on the Market in my opinion. Some people see Sarepta as a company in trouble. I see it as a multi-bagger After going through the latest numbers regulatory updates and Agree - $SRPT is my second largest long. It will rip back to $50. One of the Most Misunderstood Biotechs on the Market in my opinion. Some people see Sarepta as a company in trouble. I see it as a multi-bagger After going through the latest"
X Link 2025-12-08T03:09Z [----] followers, [---] engagements
"$RARE ascending triple top breakout today💥💥💥 $XBI long $ASND $RARE $XENE $ROIV https://t.co/dkbDCQhuu9 $XBI long $ASND $RARE $XENE $ROIV https://t.co/dkbDCQhuu9"
X Link 2025-12-08T15:03Z [----] followers, [---] engagements
"$AZN++ lots to like in this story. Look for a big year in 2026💥💥 Early findings for AstraZeneca's dual-targeted CAR-T show 100% ORR in MM #ASH25 $AZN https://t.co/ey6m2YcbyK Early findings for AstraZeneca's dual-targeted CAR-T show 100% ORR in MM #ASH25 $AZN https://t.co/ey6m2YcbyK"
X Link 2025-12-08T18:35Z [----] followers, [---] engagements
"$VKTK $NVO $LLY $GPCR $NVO with failed acquisition of MTSR I believe they will make another bold move to hunt for Obesity acquisition $VKTX or $GPCR Surprise good data from $GPCR this morning and market cap not much expensive considering MTSR recent acquisition $VKTX my bold prediction- It will $NVO with failed acquisition of MTSR I believe they will make another bold move to hunt for Obesity acquisition $VKTX or $GPCR Surprise good data from $GPCR this morning and market cap not much expensive considering MTSR recent acquisition $VKTX my bold prediction- It will"
X Link 2025-12-08T20:21Z [----] followers, [---] engagements
"$ABVX option buyers paying over $5/contract for Dec180 calls need a [--] point move in $ABVX to BREAK EVEN Crazy world $ABVX [---] C 12/19/2025 Vol: [---] OI: [---] Avg: $3.89 Prem: $310640 https://t.co/gSVzLf44Kg $ABVX [---] C 12/19/2025 Vol: [---] OI: [---] Avg: $3.89 Prem: $310640 https://t.co/gSVzLf44Kg"
X Link 2025-12-09T15:51Z [----] followers, [----] engagements
"French biotech Abivax's shares climb on Eli Lilly bid rumors Reuters. $LLY. $ABVX https://www.reuters.com/business/healthcare-pharmaceuticals/french-biotech-abivaxs-shares-climb-eli-lilly-bid-rumors-2025-12-10/ https://www.reuters.com/business/healthcare-pharmaceuticals/french-biotech-abivaxs-shares-climb-eli-lilly-bid-rumors-2025-12-10/"
X Link 2025-12-10T13:39Z [----] followers, [----] engagements
"$RBRK momentum continues to build💥💥💥 $RBRK just delivered a Top-1% AI earnings print AND triggered a Quad-MA Ignition Candle this combo is EXTREMELY rare. Most people still dont understand how insane this setup is. This wasnt a beat. This was a system-level upgrade for the entire RBRK story. Highlights that https://t.co/LSrGO6cPpH $RBRK just delivered a Top-1% AI earnings print AND triggered a Quad-MA Ignition Candle this combo is EXTREMELY rare. Most people still dont understand how insane this setup is. This wasnt a beat. This was a system-level upgrade for the entire RBRK story."
X Link 2025-12-10T14:57Z [----] followers, [---] engagements
"$LLY $ABVX the Obesity Gravy Train continues roll on for $LLY - market continues to grow & company market share continues to expand over $NVO. This gives CEO Dave Ricks the perfect opportunity to expand his product portfolio & he has the cash flow to do it. Whether hes in Paris currently dining on fine French cuisine & a hearty Bordeaux or negotiating terms with $ABVX is anybodys guess. But the key is hes in the driver seat as far as M&A and the market is likely to reward $LLY if he pulls the trigger.💥💥💥"
X Link 2025-12-10T20:56Z [----] followers, [----] engagements
"$PFE Morgan Stanley lowered their PT from $32 to $28 and lowered earnings estimates for 25/26 in front of December [--] company guidance call. The Bourla Dumpster Fire continues"
X Link 2025-12-12T14:19Z [----] followers, [---] engagements
"Democrats released a selection of photos obtained from Jeffrey Epsteins estate that include pictures of President Trump and former President Bill Clinton https://www.wsj.com/politics/democrats-release-epstein-estate-photos-showing-donald-trump-bill-clinton-7fe21bd2st=TZpYJ2 https://www.wsj.com/politics/democrats-release-epstein-estate-photos-showing-donald-trump-bill-clinton-7fe21bd2st=TZpYJ2"
X Link 2025-12-12T15:32Z [----] followers, [---] engagements
"$ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥"
X Link 2025-12-12T18:24Z [----] followers, [---] engagements
"$ATRO triple top breakout 💥💥 $ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥 $ATRO new [--] week high - the aerospace sector continues to power ahead. Visibility on orders and improving cash flow likely to keep company guidance strong💥"
X Link 2025-12-12T20:00Z [----] followers, [---] engagements
"$KYMR++ Baker Brothers bought [--] million shares @ $86/share. Among the best in biotech investing 💥💥💥 $KYMR Baker bros acquiring $172 million dollars worth of $KYMR at open market $XBI $IBB P2 Atopic dermatitis [----] https://t.co/beo19T6x5K $KYMR Baker bros acquiring $172 million dollars worth of $KYMR at open market $XBI $IBB P2 Atopic dermatitis [----] https://t.co/beo19T6x5K"
X Link 2025-12-14T23:34Z [----] followers, [---] engagements
"Sanofi's tolebrutinib woes pile up with FDA delay trial miss $SNY https://www.fiercebiotech.com/biotech/sanofis-tolebrutinib-woes-pile-fda-delay-trial-miss https://www.fiercebiotech.com/biotech/sanofis-tolebrutinib-woes-pile-fda-delay-trial-miss"
X Link 2025-12-15T17:57Z [----] followers, [---] engagements
"CoreWeaves Staggering Fall From Market Grace Highlights AI Bubble Fears - The Wall Street Journal $CRWV https://stocks.apple.com/AQc26cpqKQ9eTv-X--dKCpw https://stocks.apple.com/AQc26cpqKQ9eTv-X--dKCpw"
X Link 2025-12-16T16:15Z [----] followers, [---] engagements
"Enhertu combo cleared for use in frontline breast cancer BioPharma Dive $AZN https://www.biopharmadive.com/news/enhertu-fda-approval-first-line-her2-breast-cancer/807969/ https://www.biopharmadive.com/news/enhertu-fda-approval-first-line-her2-breast-cancer/807969/"
X Link 2025-12-16T18:01Z [----] followers, [---] engagements
"Pfizer unveils [----] guidance triggering 5% share price decline $PFE https://www.fiercepharma.com/pharma/pfizer-shares-drop-5-2026-revenue-projection-and-long-range-outlook https://www.fiercepharma.com/pharma/pfizer-shares-drop-5-2026-revenue-projection-and-long-range-outlook"
X Link 2025-12-16T20:22Z [----] followers, [--] engagements
"Gone are the bear days for biotech William Blair thinks so https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says"
X Link 2025-12-17T15:56Z [----] followers, [---] engagements
"$APLD looks like the finger in the dike is having trouble holding. It looks like short seller Jim Chanos and his message on names like $CRWV $RGTI $APLD are getting some meaningful traction"
X Link 2025-12-17T16:05Z [----] followers, [---] engagements
"$APLD cant seem to catch much of a bid continue to fall like a hot knife through butter. Sure trades like those with profits are locking them in & those who dont locking in their losses for the tax man. I guess one can always come back to $APLD if/when it settles down hard to know when $ORCL $CRWV and many others are hemorrhaging. $APLD @WUSTL_Bear are you just going to continue to let the stock fall without giving any assurance to your shareholders Down 50% since earnings and you keep saying these new hyperscaler deals are coming $APLD @WUSTL_Bear are you just going to continue to let the"
X Link 2025-12-17T23:08Z [----] followers, [---] engagements
"$ABVX Guggenheim raised TP to $175 Top Pick for [----] $ABVX . Abivax (ABVX) said late Thursday it will be added to the Nasdaq Biotechnology Index prior to market open on Dec. [--]. The index is reviewed annually in December and is calculated under a modified capitalization-weighted methodology the clinical-stage biotechnology https://t.co/QL7YLa4fHE $ABVX . Abivax (ABVX) said late Thursday it will be added to the Nasdaq Biotechnology Index prior to market open on Dec. [--]. The index is reviewed annually in December and is calculated under a modified capitalization-weighted methodology the"
X Link 2025-12-19T14:18Z [----] followers, [----] engagements
"Kennedy Center adds Trumps name to building https://www.washingtonpost.com/entertainment/2025/12/19/trump-kennedy-center-sign/ https://www.washingtonpost.com/entertainment/2025/12/19/trump-kennedy-center-sign/"
X Link 2025-12-19T15:58Z [----] followers, [--] engagements
"$CYTK Nice seeing $GS getting back into game Upgrade BUY $95 PT For those not awareone of the smartest healthcare teams (TRowePrice) now hold over [--] million shares bought over the last [--] months and have become the #1 institutional holder. If walls could only speak . [----] will be a wonderful year for $CYTK and their shareholders 💥 Goldman Sachs $CYTK to Buy/$95 from Neutral/$55 $BMY $EWTX Goldman Sachs said: Emerging data cuts from ODYSSEY-HCM increasingly support a view BMY' trial missed primarily due to drug exposure and study execution issues rather than mechanistic issues with cardiac"
X Link 2025-12-19T16:12Z [----] followers, [----] engagements
"$INFY is Santa Claus coming to town What up here Is crazy man Trump doing something with HB1 visas Are his friends getting in front of an announcement Sure wouldnt be the first time what is happening in #INFY #ADR up 40% https://t.co/AnTCLKOz2Q what is happening in #INFY #ADR up 40% https://t.co/AnTCLKOz2Q"
X Link 2025-12-19T16:21Z [----] followers, [---] engagements
"$ABVX the story continues to unfold💥💥💥 $ABVX Obe acting directly on fibroblasts is totally unexpected. It suggests: A 2-pronged mechanism particularly relevant for CD Cell-based proof for the holy grail in CD - reversal of fibrosis It makes CD prospects much more interesting with Obe as a potential game changer https://t.co/MYAKKmE8wg $ABVX Obe acting directly on fibroblasts is totally unexpected. It suggests: A 2-pronged mechanism particularly relevant for CD Cell-based proof for the holy grail in CD - reversal of fibrosis It makes CD prospects much more interesting with Obe as a"
X Link 2025-12-19T18:12Z [----] followers, [----] engagements
"Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYTK https://www.biospace.com/drug-development/cytokinetics-moment-of-truth-can-aficamten-take-on-bms-in-hypertrophic-cardiomyopathy https://www.biospace.com/drug-development/cytokinetics-moment-of-truth-can-aficamten-take-on-bms-in-hypertrophic-cardiomyopathy"
X Link 2025-12-19T19:35Z [----] followers, [---] engagements
"$CYTK Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYKT https://t.co/xMdG0kUtTv Cytokinetics Moment of Truth: Can Aficamten Take On BMS in Hypertrophic Cardiomyopathy $CYKT https://t.co/xMdG0kUtTv"
X Link 2025-12-19T19:36Z [----] followers, [----] engagements
"$CYTK solid label will favor Aficamten with prescribing physicians. They know the game and the hoops they have to go through with $BMY Camzyous. Now patients have a more efficacious option with better data backing it up. When we get the data from AcaciaHCM if it is positive will give $CYTK the throne in both nHCM and oHCM. This will lead to an awesome [----] and shareholders and HCM patients will amply rewarded💥💥💥 $CYTK compares well to Camzyos Here is Camzios box warning Key differences: Reduce dose of aficamten (CYTK) if LVEF [--] Interrupt [--] Camzios - interrupt [--] Camzios has other"
X Link 2025-12-20T04:21Z [----] followers, [----] engagements
"$CYTK the outlook continues to be stronger for MyQorzo as the FDA approval is granted. [----] has the potential to be a big year for investors with the ACACIA-HCM results on the horizon. Look for a packed house when they present at JPM Healthcare Conference in mid January. I will bet dollars to donuts that BigBioPharma is doing a deep analysis on this one💥💥💥 $CYTK Cantor Impact valuation.peak overall revenue estimates have increased to $7.2bn (from $6.7bn) with peak WW Myqorzo sales of $6.0bn (from $5.5bn) roughly 70% from oHCM. value $CYTK shares using a sum-of-the-parts NPV analysis (10%"
X Link 2025-12-22T03:04Z [----] followers, [----] engagements
"$AZN no sleeping on AstraZeneca. They are being aggressive on every front & have demonstrated the muscle to attack on every sector. I like their financial discipline and strategic planning. Momentum looks solid in 2026💥💥💥 $AZN is going after $RVMD with preclinical assets from China 👍 jab-23e73 currently in ph1/2a Expected completion 11-2027 (1a/b) and 02-2028 (2a) [--] cohorts: CRC PRAC Other solids $AZN is going after $RVMD with preclinical assets from China 👍 jab-23e73 currently in ph1/2a Expected completion 11-2027 (1a/b) and 02-2028 (2a) [--] cohorts: CRC PRAC Other solids"
X Link 2025-12-22T04:21Z [----] followers, [---] engagements
"$ABVX $LLY it sure looks like momentum for an acquisition is continuing 🚀🚀🚀 French newspaper with some breaking news this morning $abvx US Giant Eli Lilly Courts Bercy in Move to Acquire Biotech Firm Abivax A delegation from the pharmaceutical group visited the General Directorate of the Treasury in early December. The meeting was intended to subject a https://t.co/6oCy2kp0Gu French newspaper with some breaking news this morning $abvx US Giant Eli Lilly Courts Bercy in Move to Acquire Biotech Firm Abivax A delegation from the pharmaceutical group visited the General Directorate of the"
X Link 2025-12-22T13:11Z [----] followers, [----] engagements
"$CYTK if Aficamten can follow up with positive data from ACACIA-HCM as GS sees as likely - it will position the company to be able to address BOTH oHCM and nHCM. This will be greeted as great news by investors and increase the attractiveness to BigBioPharmas for sure. [----] looks to be a potentially great year for $CYTK💥💥💥 $CYTK GS Emerging data cuts from ODYSSEY-HCM increasingly support a view $BMY' trial missed primarily due to drug exposure &study execution issues rather than mechanistic issues with cardiac myosin inhibitionthinks that CYTK has likely addressed these issues with"
X Link 2025-12-22T14:45Z [----] followers, [---] engagements
"Cytokinetics set to battle Bristol Myers as FDA approves heart drug - BioPharma Dive $CYTK https://stocks.apple.com/ACFrW9kquRG6X67JCXodqlA https://stocks.apple.com/ACFrW9kquRG6X67JCXodqlA"
X Link 2025-12-22T15:03Z [----] followers, [---] engagements
"AstraZeneca fronts $100M for Jacobio's pan-KRAS inhibitor $AZN https://www.fiercebiotech.com/biotech/astrazeneca-fronts-100m-jacobios-clinical-stage-pan-kras-inhibitor https://www.fiercebiotech.com/biotech/astrazeneca-fronts-100m-jacobios-clinical-stage-pan-kras-inhibitor"
X Link 2025-12-22T18:08Z [----] followers, [---] engagements
"Biotechs top [--] stock picks for 2026: analyst. $TERN https://www.fiercebiotech.com/biotech/top-5-stock-picks-biotech-2026-william-blair https://www.fiercebiotech.com/biotech/top-5-stock-picks-biotech-2026-william-blair"
X Link 2025-12-23T20:58Z [----] followers, [---] engagements
"$CYTK if Aficamten gets approval in nHCM after a positive showing from the ACACIAHCM data then there are likely multiple bidders besides $NVS. Lots of upside left in this one in 2026💥💥💥 $cytk If $nvs can buy $rna at 12B then $CYTK (Mcap around 8B) is not beyond their reach either. There are hardly few derisked assets in market https://t.co/Zo0D1pn2HB $cytk If $nvs can buy $rna at 12B then $CYTK (Mcap around 8B) is not beyond their reach either. There are hardly few derisked assets in market https://t.co/Zo0D1pn2HB"
X Link 2025-12-24T21:17Z [----] followers, [----] engagements
"Coupang Stock Rallies After Company Says Data Breach Less Severe Than Initially Feared $CPNG https://www.investors.com/news/technology/coupang-stock-data-breach-investigation/ https://www.investors.com/news/technology/coupang-stock-data-breach-investigation/"
X Link 2025-12-27T21:15Z [----] followers, [---] engagements
"$CPNG looks like risk/reward looks attractive on the upside over the short term💥💥💥 🗓 Watchlist for Mon Dec [--] $GSIT $SKYT $ACOG $XPEV $ZURA $FBRX $LBRX $CPNG $CMTL $ALMU 📌 See pinned tweet for how I use my WL. NFA. https://t.co/TgB2sK9deF 🗓 Watchlist for Mon Dec [--] $GSIT $SKYT $ACOG $XPEV $ZURA $FBRX $LBRX $CPNG $CMTL $ALMU 📌 See pinned tweet for how I use my WL. NFA. https://t.co/TgB2sK9deF"
X Link 2025-12-29T04:33Z [----] followers, [---] engagements
"$AZN++ one of the best plays in BigBioPharma 💥💥💥 $AZN Cowen Best Ideas 2026: Broad-Based Strengths Poised To Deliver Above Average Growth Buy $AZN has promising new products and pipeline and participates in many large high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth appears to be $AZN Cowen Best Ideas 2026: Broad-Based Strengths Poised To Deliver Above Average Growth Buy $AZN has promising new products and pipeline and participates in many large high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth"
X Link 2025-12-29T12:44Z [----] followers, [---] engagements
"$ABVX this presentation was likely set up a while back. It would not surprise me if the company had to cancel. BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A dynamics ahead of #JPM26; cross-border M&A under new US tariff rules; and how to approach BPs for a deal. Link👇 https://t.co/ME3eKey568 BOOM💥Marc to discuss M&A info publicly. $ABVX CEO Marc along with top sell-side advisor Centerview will attend an M&A-related webinar on Jan [--]. Topics: M&A dynamics ahead of #JPM26;"
X Link 2025-12-30T21:58Z [----] followers, [----] engagements
"$AXSM++ what a beautiful story💥💥💥 $AXSM Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimers Disease Agitation Axsome Therapeutics Inc. https://t.co/uAJ4OqsFZ2 $AXSM Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimers Disease Agitation Axsome Therapeutics Inc. https://t.co/uAJ4OqsFZ2"
X Link 2025-12-31T15:03Z [----] followers, [---] engagements
"$AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥 $AZN JP Morgan expects solid AstraZeneca quarter and reassuring outlook https://t.co/w9ihVe6Dot #AZN $AZN JP Morgan expects solid AstraZeneca quarter and reassuring outlook https://t.co/w9ihVe6Dot #AZN"
X Link 2026-01-06T15:30Z [----] followers, [---] engagements
"$AZN blasting through to a new [--] week high🚀🚀🚀 $AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥 $AZN++ look for future guidance from upcoming Q results to be strong💥💥💥💥"
X Link 2026-01-06T15:51Z [----] followers, [---] engagements
"AZ looks to grow reach in lupus with phase [--] win for self-administered Saphnelo Fierce Pharma. $AZN https://www.fiercepharma.com/pharma/astrazeneca-eyes-leg-lupus-market-phase-3-win-self-administered-saphnelo https://www.fiercepharma.com/pharma/astrazeneca-eyes-leg-lupus-market-phase-3-win-self-administered-saphnelo"
X Link 2026-01-06T19:46Z [----] followers, [---] engagements
"Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire $CYTK should be standing room only crowd https://stocks.apple.com/AH54WeiwwRoewgb_c-1xfIg https://stocks.apple.com/AH54WeiwwRoewgb_c-1xfIg"
X Link 2026-01-06T23:23Z [----] followers, [---] engagements
"JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors - January [--] [----] - $AZN $JNJ https://www.zacks.com/stock/news/2812761/jnj-vs-azn-which-drug-stock-comes-out-on-top-for-investors http://Zacks.com https://www.zacks.com/stock/news/2812761/jnj-vs-azn-which-drug-stock-comes-out-on-top-for-investors http://Zacks.com"
X Link 2026-01-06T23:29Z [----] followers, [---] engagements
"$CYTK++ MS reiterates OW and raises TP to $90 from $71. Look for managements update presentation at J.P. Morgan Healthcare Conference next week💥💥💥💥 $CYTK MS at $90 Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in [----] as commercial names transition $CYTK MS at $90 Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The"
X Link 2026-01-08T13:33Z [----] followers, [---] engagements
"$AZN++ [----] is shaping up to be another great year Cowen💥💥 $AZN COWEN #Pharma-12 Events In [----] That Could Change Practice Alter Companies Move Stocks-In [----] Pharma has many events with $1B+ potential; here highlight the top [--] (+ one for the pets) and rank them by likelihood to move stocks. $AZN is the only company with three $AZN COWEN #Pharma-12 Events In [----] That Could Change Practice Alter Companies Move Stocks-In [----] Pharma has many events with $1B+ potential; here highlight the top [--] (+ one for the pets) and rank them by likelihood to move stocks. $AZN is the only company with"
X Link 2026-01-08T14:27Z [----] followers, [---] engagements
"$ATEC++ double top breakout & new [--] week high💥💥💥 "Nobody can predict interest rates the future direction of the economy or the stock market. Dismiss all such forecasts and concentrate on what's actually happening to the companies in which you've invested" Peter Lynch $ATEC criteria: Volume https://t.co/VjAqg7mNyc "Nobody can predict interest rates the future direction of the economy or the stock market. Dismiss all such forecasts and concentrate on what's actually happening to the companies in which you've invested" Peter Lynch $ATEC criteria: Volume https://t.co/VjAqg7mNyc"
X Link 2026-01-08T16:35Z [----] followers, [---] engagements
"$AZN double top breakout this week along with new [--] week/ all-time high💥💥💥 $AZN++ [----] is shaping up to be another great year Cowen💥💥 $AZN++ [----] is shaping up to be another great year Cowen💥💥"
X Link 2026-01-08T16:39Z [----] followers, [---] engagements
"Lightning Round: I think you should own Rubrik says Cramer - CNBC $RBRK https://stocks.apple.com/A2_cRuD3WTgCHbZLq588zpA https://stocks.apple.com/A2_cRuD3WTgCHbZLq588zpA"
X Link 2026-01-08T17:02Z [----] followers, [---] engagements
"$CYTK A very compelling story. TRowe Pricevery smart healthcare investors bought up 20% of the stock. What do you think they know💥💥💥 Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26. $BMY $EWTX Jefferies added If successful it could open up aficamten in nHCM which Jefferies $CYTK's PT to $90 from $80 reiterated at Buy and said CYTK's upcoming Ph.3 study ACACIA in non-obstructive HCM (nHCM) is one of the biggest readouts in SMID cap biotech in 1H'26."
X Link 2026-01-09T14:07Z [----] followers, [---] engagements
"$SRPT lets see what management has to say at their J.P. Morgan healthcare conference presentation 💥💥💥 $SRPT continues it's march towards $50. https://t.co/CbVYbtxJb1 $SRPT continues it's march towards $50. https://t.co/CbVYbtxJb1"
X Link 2026-01-09T16:16Z [----] followers, [---] engagements
"$VKTX their day in the sun will come. The data is the data the best safety & efficacy of all the players. Most are confused on whether they bring VK2735 to market alone or sell their position to a large BioPharma. Management knows the value is there as do many holders. How it will play out in [--] is anyones guess. I believe this will be an important year for investors as the $100+billion DiaBesity market continues to expand to more indications and continues to grow. I like the story $VKTX $LLY $NVO The mouth-pieces for the orals that cant hold a candle to Vikings oral will grow louder before"
X Link 2026-01-11T03:50Z [----] followers, [----] engagements
"$ABVX $LLY dont close the door on this one $LLY remains an extremely well-financed suitor who appears to be well aware of the process in purchasing a French company. They also have the capabilities to manufacture market & provide the scientific support to make a this a successful product launch in Ulcerative Colitiscapabilities $ABVX does not have. Lets get this party started🚀🚀🚀 Huge tells from the $ABVX CEO interview just now. When asked about $LLY meeting with the French Treasury he didnt deny it. Instead he gave us the roadmap: [--]. Confirmed that the FDI (Foreign Direct Investment)"
X Link 2026-01-12T03:35Z [----] followers, [----] engagements
"Abivax Surges on Report Eli Lilly is Preparing $17.5 Billion Bid $ABVX https://www.wsj.com/health/pharma/abivax-surges-on-report-ely-lily-is-preparing-17-5-billion-bid-119a6fc7st=VXdcDU https://www.wsj.com/health/pharma/abivax-surges-on-report-ely-lily-is-preparing-17-5-billion-bid-119a6fc7st=VXdcDU"
X Link 2026-01-12T12:29Z [----] followers, [---] engagements
"$VKTX new data looks attractive- looks to be a favorable risk/reward for this small cap gem💥💥 📢 : $VKTX Vikings VK2735 Shows Up to 14.7% Weight Loss in [--] Weeks 👉 : ➤ (NASDAQ: VKTX) publishes Phase [--] results in journal. ➤ achieved up to .% 📢 : $VKTX Vikings VK2735 Shows Up to 14.7% Weight Loss in [--] Weeks 👉 : ➤ (NASDAQ: VKTX) publishes Phase [--] results in journal. ➤ achieved up to .%"
X Link 2026-01-12T14:11Z [----] followers, [----] engagements
"$TGTX it would be no surprise if the company is putting its $100 mil stock purchase plan to work just as they did the last time it was at these levels. Lets see what CEO MW has to say at the JPM Healthcare Conference. Im sure there will be many interested observers"
X Link 2026-01-12T14:58Z [----] followers, [---] engagements
"$PFE this management team is clearly the gang that cannot shoot straight & will once again underperform in [----]. I would be surprised if Bourla is still around a year from now. Activist investor Starboard has not seen any return on their $ billion position & will either exit or push for new management. What a sad story. $PFE @AlbertBourla at JPM affirmed Versper [--] results this year Previous Metsera guidance was late [----] and later from Pfizer was q1 [---]. It is [--] months of escalation and [--] monthly. Unfortunately and based on previous [--] and [--] wk data efficacy should be modest and likely"
X Link 2026-01-12T20:32Z [----] followers, [---] engagements
"$AXSM the easy $$ may have been made but the story remains on solid footing as the venue and earnings continues to ramp up nicely 💥💥💥 $AXSM Total preliminary Q4 and FY'25 net product revenue of $196M and $638M respectively representing 65% and 66% annual growth AUVELITY preliminary FY'25 $507M SUNOSI FY'25 net product rev $124.8M $AXSM Total preliminary Q4 and FY'25 net product revenue of $196M and $638M respectively representing 65% and 66% annual growth AUVELITY preliminary FY'25 $507M SUNOSI FY'25 net product rev $124.8M"
X Link 2026-01-12T20:39Z [----] followers, [---] engagements
"$ABVX JPM weighs in the potential purchase of Abivax by $LLY and likes the combination 👍 JPM:" Quick Thoughts on $LLY s Reported Interest in Abivax $ABVX ." https://t.co/qI4dkFdiLF JPM:" Quick Thoughts on $LLY s Reported Interest in Abivax $ABVX ." https://t.co/qI4dkFdiLF"
X Link 2026-01-13T15:40Z [----] followers, [----] engagements
"$AZN AstraZeneca brings Modella AI in-house to power oncology R&D $AZN https://t.co/Iq3XLH1a08 AstraZeneca brings Modella AI in-house to power oncology R&D $AZN https://t.co/Iq3XLH1a08"
X Link 2026-01-14T04:54Z [----] followers, [---] engagements
"$TGTX the growth story remains intact. Can we please get a little more respect from investorsplease🙏 $TGTX Preliminary total global full year [----] revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year [----] net product revenue of approximately $182 million and $594 million respectively Full Year [----] target total global revenue of $TGTX Preliminary total global full year [----] revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year [----] net product revenue of approximately $182 million and $594 million respectively Full"
X Link 2026-01-14T05:00Z [----] followers, [---] engagements
"FDA approves AZ/Daiichi's Enhertu in 1st-line HER2 breast cancer $AZN https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyo-score-fda-nod-enhertu-combo-breast-cancer https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyo-score-fda-nod-enhertu-combo-breast-cancer"
X Link 2026-01-14T13:39Z [----] followers, [----] engagements
"$AZN the momentum continues to ramp in [----]. Hard to find anyone in BigBioPharma with a story like this💥💥💥 $AZN #JPM26 [--] positive phase [--] readouts since [----] with another [---] phase [--] trials to readout $AZN #JPM26 [--] positive phase [--] readouts since [----] with another [---] phase [--] trials to readout"
X Link 2026-01-14T13:45Z [----] followers, [---] engagements
"$TGTX JPM reiterated BUY $49 PT raising earnings & revenue estimates 💥💥 $TGTX JP BUY PT$49 #JPM26 Briumvi US sales 4Q beat; Focus on [----] guidance. 4Q US Briumvi sales were $182mn (+19% q/q) which came in above JPMe $177mn. Initial FY26 total WW guidance of $875-900mn comprised of $825-850mn Briumvi US net sales. Mgmt noted that [----] q/q cadence $TGTX JP BUY PT$49 #JPM26 Briumvi US sales 4Q beat; Focus on [----] guidance. 4Q US Briumvi sales were $182mn (+19% q/q) which came in above JPMe $177mn. Initial FY26 total WW guidance of $875-900mn comprised of $825-850mn Briumvi US net sales. Mgmt"
X Link 2026-01-14T18:54Z [----] followers, [---] engagements
"AZ's $80B revenue target 'very much within reach' CFO says $AZN https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says https://www.fiercepharma.com/pharma/astrazeneca-80-billion-revenue-target-very-much-within-reach-cfo-says"
X Link 2026-01-14T19:16Z [----] followers, [---] engagements
"Costco Executives Have Been Selling Stock on the Heels of a Rough [----] - Barron's. $COST https://www.barrons.com/articles/costco-execs-stock-sales-f9e586cc https://www.barrons.com/articles/costco-execs-stock-sales-f9e586cc"
X Link 2026-01-15T05:26Z [----] followers, [--] engagements
"$OCUL $SNY speculation of buyout offer #LaLettre: $SNY makes fresh play for $OCUL. The French pharmaceutical group and its chief executive Paul Hudson are preparing an improved bid to acquire the US biotech start-up. Its initial offer of$16 per share was rejected by the US biotech's board. https://t.co/REAR4tEG6X #LaLettre: $SNY makes fresh play for $OCUL. The French pharmaceutical group and its chief executive Paul Hudson are preparing an improved bid to acquire the US biotech start-up. Its initial offer of$16 per share was rejected by the US biotech's board. https://t.co/REAR4tEG6X"
X Link 2026-01-15T12:48Z [----] followers, [---] engagements
"JPM26 Day 3: AbbVie touts 'clear line of sight' to continued growth into 2030s Fierce Pharma $ABBV https://www.fiercepharma.com/pharma/fierce-pharmas-jpm26-tracker-day-3 https://www.fiercepharma.com/pharma/fierce-pharmas-jpm26-tracker-day-3"
X Link 2026-01-15T18:07Z [----] followers, [---] engagements
"TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally. TGTX https://stocktwits.com/news-articles/markets/equity/tgtx-stock-pops-as-briumvi-boom-reignites-bull-case-goldman-sachs-sees-room-for-32-rally/cmU1fZAR470 https://stocktwits.com/news-articles/markets/equity/tgtx-stock-pops-as-briumvi-boom-reignites-bull-case-goldman-sachs-sees-room-for-32-rally/cmU1fZAR470"
X Link 2026-01-16T01:36Z [----] followers, [---] engagements
"$VKTX this one is like a coiled spring that will snap to the upside when people least expect it. Every large BioPharma absolutely knows that DiaBesity is the $150+ Billion market where they must have a LEGITIMATE presence. Dont sell this $3.5 billion small cap shortthe risk/reward upside is substantial 💥💥💥 $GPCR hit $90 in after hours trading session 😍😍 Recall stock price was bearish for a long time Market cycle frustrates many investors and traders followed by a huge rally $VKTX has all the ingredients too for a successful comeback and it will. Own $VKTX & $GPCR Obesity $GPCR hit $90 in"
X Link 2026-01-16T01:53Z [----] followers, [----] engagements
"$VKTX CEO BL is anything but shy. I would rather say strategic as he is a Wall Street guy who knows how the game is played. Rather than sellout early hes made the decision to shepherd VK2735 through the clinical trialsknowing that hes creating more value along the way. There are numerous major players who would like to buy them but hes not a seller until he can get the price he wants. There remains a lot of upside if anyone has any patience💥💥 @Pharmdca $VKTX has a shy CEO who clearly not helping company PR ( although executing great at progressing assets ) Long term good drugs will prevail"
X Link 2026-01-16T02:04Z [----] followers, [----] engagements
"$TGTX risk/reward outlook through [----] looks to be quite favorable. The BRIUMVI franchise continues to accelerate & revenues cash flow & EPS remains on the upswing. Dont give up on this small cap gem💥💥💥 $TGTX TG is at an inflection point where for the next few years there will be meaningful cash flows even with the subQ Briumvi launch. estimate $400-$700M in annual cash flow in next few years increasing to $900M-$1B by [----]. $TGTX TG is at an inflection point where for the next few years there will be meaningful cash flows even with the subQ Briumvi launch. estimate $400-$700M in annual"
X Link 2026-01-16T13:41Z [----] followers, [---] engagements
"$CPNG Deutsche Bank upgraded to BUY saying that most of the regulatory uncertainties have been priced in $CPNG looks super compelling here already filled some gaps now bouncing off VWAPs and trendlines from the [----] lows. there were also some block trades on the tape yesterday that suggest some big buyers are starting to accumulate. $CPNG trading below 18x [----] EV/EBITDA with https://t.co/BBYIEODyQA $CPNG looks super compelling here already filled some gaps now bouncing off VWAPs and trendlines from the [----] lows. there were also some block trades on the tape yesterday that suggest some big"
X Link 2026-01-16T13:47Z [----] followers, [---] engagements
"$MMM BofA TOP PICK raise PT $200/sh. We expect a Q beat on 1/20 and see better growth performance driven by self help initiatives"
X Link 2026-01-16T14:07Z [----] followers, [---] engagements
"$RBRK [----] looks to be a very good year. Risk/reward looks quite favorable from current levels💥💥 $RBRK stock is now back to pre-Q3 levels. Meanwhile: 🔹Subscription revenue grew 52% 🔹Free cash flow is up +347% 🔹Net retention is 120% A great business at a very reasonable price in my opinion. https://t.co/A2Q1qxBfEg $RBRK stock is now back to pre-Q3 levels. Meanwhile: 🔹Subscription revenue grew 52% 🔹Free cash flow is up +347% 🔹Net retention is 120% A great business at a very reasonable price in my opinion. https://t.co/A2Q1qxBfEg"
X Link 2026-01-16T14:29Z [----] followers, [---] engagements
"$AZN $ASML $RHBBY - all [--] are powering the European markets 💥 Here are the top holdings in $EFA iShares MSCI EAFE ETF: 🥇 ASML Holding $ASML 2.3% 🥈 AstraZeneca $AZN 1.4% 🥉 Roche Holding $ROG 1.4% https://t.co/cMnbwFV4bI Here are the top holdings in $EFA iShares MSCI EAFE ETF: 🥇 ASML Holding $ASML 2.3% 🥈 AstraZeneca $AZN 1.4% 🥉 Roche Holding $ROG 1.4% https://t.co/cMnbwFV4bI"
X Link 2026-01-18T21:18Z [----] followers, [---] engagements
"JPM26: Biotechs M&A lift the new Biogen and Mercks $70B target BioPharma Dive $BGEN $MRK $SMMT https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/ https://www.biopharmadive.com/news/jpm26-biogen-gilead-merck-cidara-moderna-summit/809446/"
X Link 2026-01-20T13:37Z [----] followers, [---] engagements
"$ABVX games people play $ABVX Abivax CEO dismisses noise around rumored $LLY bid. "There was no discussion on the acquisition of Abivax. . if there was a conversation this would be illegal." https://t.co/p3VfkSmodA $ABVX Abivax CEO dismisses noise around rumored $LLY bid. "There was no discussion on the acquisition of Abivax. . if there was a conversation this would be illegal." https://t.co/p3VfkSmodA"
X Link 2026-01-20T15:22Z [----] followers, [---] engagements
"AstraZeneca pens $630M pact for remaining China rights to CAR-T. $AZN https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t https://www.fiercebiotech.com/biotech/astrazeneca-pens-630m-pact-secure-remaining-rights-armored-car-t"
X Link 2026-01-21T15:51Z [----] followers, [---] engagements
"$MRNA BofA king putz ANALyst Stranahan reits his UNDERPERFORM $27 PT today. I guess stock performance (+60% past month) means nothing. Makes you wonder how a clown like this gets a paycheck. $MRNA +15% today on strong cancer vaccine data Moderna is ripping higher after new long-term data showed its personalized cancer vaccine used together with $MRKs Keytruda continues to deliver meaningful benefits. Key takeaway: - The Moderna + Merck combo cut the risk of https://t.co/Q6z0uuKlTX $MRNA +15% today on strong cancer vaccine data Moderna is ripping higher after new long-term data showed its"
X Link 2026-01-22T16:11Z [----] followers, [---] engagements
"Moderna Stock Soars. Why a Cancer Vaccine Study Has Sparked a Rally. - Barron's $MRNA BofA reiterate UNDERPERFORM $27 PT https://www.barrons.com/articles/moderna-stock-rally-cancer-vaccine-study-merck-2ae374ae https://www.barrons.com/articles/moderna-stock-rally-cancer-vaccine-study-merck-2ae374ae"
X Link 2026-01-23T04:00Z [----] followers, [---] engagements
"Sanofi posts mixed phase [--] data on key eczema prospect $ SNY https://www.fiercebiotech.com/biotech/sanofi-posts-mixed-phase-3-data-key-eczema-prospect-plans-global-filings https://www.fiercebiotech.com/biotech/sanofi-posts-mixed-phase-3-data-key-eczema-prospect-plans-global-filings"
X Link 2026-01-23T17:14Z [----] followers, [---] engagements
"Novo's Wegovy pill launch wows with strong early uptake: analysts $NVO https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says"
X Link 2026-01-23T17:26Z [----] followers, [---] engagements
"$VKTX lots of triggers on the horizon in [----] getting ready for PRIME TIME💥💥💥 $VKTX OPPY hosted CEO Brian Lian &new CCO Neil Aubuchon for a group call discussing recent progress and key catalysts ahead. Neil highlighted promising profiles of both subQ and oral VK2735 and views VKTX's unique setting having both subQ and oral formulations as an important $VKTX OPPY hosted CEO Brian Lian &new CCO Neil Aubuchon for a group call discussing recent progress and key catalysts ahead. Neil highlighted promising profiles of both subQ and oral VK2735 and views VKTX's unique setting having both subQ"
X Link 2026-01-23T22:26Z [----] followers, [----] engagements
"$SRPT lets see what the company has to say on their Monday call $SRPT For a long time the loudest claim has been that Elevidys doesnt work. But parents keep showing up again and again to defend this therapy unprompted unpaid and with nothing to gain. People dont do that for something that doesnt work https://t.co/AhNrWvEZ5M $SRPT For a long time the loudest claim has been that Elevidys doesnt work. But parents keep showing up again and again to defend this therapy unprompted unpaid and with nothing to gain. People dont do that for something that doesnt work https://t.co/AhNrWvEZ5M"
X Link 2026-01-25T22:55Z [----] followers, [---] engagements
"$SRPT $SRPT Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients https://t.co/ZnVCNYjcNt $SRPT Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients https://t.co/ZnVCNYjcNt"
X Link 2026-01-26T13:27Z [----] followers, [---] engagements
"Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys - Barrons. $SRPT https://stocks.apple.com/AOJRgK3tEQ4Kv0JFuo16OfA https://stocks.apple.com/AOJRgK3tEQ4Kv0JFuo16OfA"
X Link 2026-01-26T15:43Z [----] followers, [---] engagements
"Sarepta battling slowing sales claims Duchenne gene therapys impact grows with time BioPharma Dive. $SRPT https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/ https://www.biopharmadive.com/news/sarepta-elevidys-duchenne-gene-therapy-embark-data/810461/"
X Link 2026-01-26T18:17Z [----] followers, [---] engagements
"@stocktilludrop @mikegoodma If you invest in growth stocks you invest in growing companies. $GILDs pipe is uninspiring"
X Link 2016-01-29T02:49Z [----] followers, [--] engagements
"@SellSideSource WOW ---- I call that "leading edge research" Surprised GS even noticed --- though did recommend that $ALXN spend $8.4 Billion on $GEVA ---- excellent due diligence there"
X Link 2018-03-15T13:04Z [----] followers, [--] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing